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BIOPHYSICAL EXPLORATION OF CONFORMATIONAL ENVIRONMENTS IN 
ZYMOGEN PROTHROMBIN AND BLOOD COAGULANT THROMBIN 
Ramya Billur 
April 30, 2018 
 
The serine protease thrombin plays important roles in coagulation, anticoagulation, 
and platelet activation. Thrombin is initially expressed as the inactive zymogen 
prothrombin (ProT). The final cleaved and activated form of thrombin has mature anion 
binding exosites (ABEs) and several regulatory loops. Engagement with these exosites 
helps define the fate of thrombin as a procoagulant or an anticoagulant. Researchers 
previously reported that zymogen ProT may already bind exosite ligands. Little is known 
about conformational changes associated with ProT maturation, resultant ligand binding 
affinities, individual ligand-protein contacts, and long-range communication between 
thrombin exosites.  
Protease Activated Receptors (PARs) play critical roles in controlling platelet 
activation. Using solution NMR methods, we demonstrated that PAR3 (44-56) and weaker 
binding version PAR3G (44-56, P51G) can already bind to immature pro-ABE I. 1D and 
2D 1H-15N HSQC titrations revealed that PAR3G 15N-E48 and 15N-D54 both entered into 
higher affinity, intermediate exchange regimes as ProT was converted into thrombin. The 




binding than thrombin R75. PAR3G 15N-F47 and 15N-L52 experienced significant changes 
in chemical shift and thus chemical environment upon ABE I maturation. However, the 
ProT 30s loop made better contacts with PAR3 than the ProT hydrophobic cluster (F34, 
L65, and I82).  
The project was extended to PAR1 (49-62). Both PAR1P and weaker version 
PAR1G (P54G) bound to ProT and proton NMR line broadening increased with thrombin. 
1D and 2D 1H-15N HSQC titrations revealed that unlike PAR3G (44-56), PAR1G (49-62) 
15N- K51, E53, F55, D58, and E60 exhibited little interactions with ProT. Affinities 
increased with mature thrombin ABE I. NMR titrations could probe PAR1 (58DEEKN62), 
a region previously unresolved by X-ray crystallography. Interestingly, the ABE II ligand 
GpIbα (269-282, 3YP) influenced the NMR binding affinities of PAR1G and PAR3G 
supporting long-range communication between the ABE II and ABE I exosites. Finally, 
our studies shifted toward the thrombin active site region.  Kinetic assays and 2D tr-
NOESY studies provided clues on why Fibrinogen Bβ (5-16) is such a weak thrombin 
substrate.  The Fibrinogen Bβ 10FFSAR14 sequence contributes towards hindering binding 
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Over time, an important host defense mechanism that highly evolved vertebrates 
adopted was hemostasis. Hemostasis can be defined as a mechanism for formation of a 
blood clot at the site of vascular injury, while not disturbing the blood flow throughout the 
rest of the body. During a vascular injury, platelet interactions with several clotting factors, 
red blood cells, and white blood cells forms a protective plug, which stops the flow of 
blood. To maintain balance, fibrinolytic mechanisms also evolved to degrade the clot and 
restore normal blood flow in the injured blood vessels.1,2 
Since the 1800s, blood coagulation has been recognized as an important biological 
phenomenon and has drawn the attention of many world class biochemists and physicians.3 
Over the years, there were debates about the different nomenclatures being used for clotting 
factors. All this came to an end by the establishment of a standard nomenclature approved 
by an international committee and now regularly reviewed by the ISTH (International 
Society on Thrombosis and Hemostasis). For most of the clotting factors, a Roman 
Numeral nomenclature was assigned based on their time of discovery.4  This chapter will 
highlight the various coagulation pathways, the individual clotting factors, and the 






Blood coagulation cascade 
Fibrinogen, also called factor I, was the first factor isolated and is an abundant 
glycoprotein in plasma.5,6  Fibrin is formed by the limited proteolysis of fibrinogen and 
followed by polymerization. Fibrin is the only coagulation protein whose existence has not 
been debated. Schmidt isolated fibrin ferment from fresh serum and later named the 
reactive component as thrombin. This thrombin was proposed to polymerize fibrinogen 
when tissue extracts could not convert fibrinogen to fibrin.3  The discovery of prothrombin 
(factor II or ProT), through differential precipitation strategies from blood, led the 
researchers to believe that thrombin cannot be extracted from blood. Thrombin must 
instead be generated from ProT following limited proteolysis.7-10  Morawitz developed a 
classical theory of blood coagulation. He proposed a four-factor theory, where tissue factor, 
also called thromboplastin (or thrombokinase), converts ProT to thrombin in the presence 
of calcium ions. Later, the activated thrombin converts fibrinogen into a meshy clot called 
fibrin. This four-factor theory was accepted for 50 years.4,11  However in 1947 based on a 
natural clotting defect, Owren put an end to the classical theory by concluding that normal 
plasma needs another factor to complete the action of thromboplastin. Further research led 
to the discovery of factor V (Proaccelerin).12  Later, additional natural clotting defects led 
to the discovery of factors VII and X (Stuart-Prower factor). At the same time, a 
phospholipid environment was identified as being important in the conversion of 
prothrombin to thrombin. Biggs, Douglas, and Macfarlane demonstrated that haemophilic 
blood cannot produce fibrin.13,14  They also showed that fibrin production can be triggered 
by adding antihaemophilic globulin that was later found to contain factor VIII 




discoveries of clotting factors IX (Christmas factor), XI (PTA, Plasma Thromboplastin 
Antecedant) and XII (Hageman factor). Laki and Lorand partially purified a fibrin-
stabilizing factor which is now called factor XIII.19  Chen and Doolittle subsequently 
identified that factor XIII has transglutaminase activity and is responsible for the formation 
of cross links between fibrin monomers.20 
In 1964, Macfaralane incorporated the newly discovered proteins into an updated 
blood coagulation cascade.11  He classified the cascade into two pathways: Intrinsic and 
Extrinsic. As the name suggests, the intrinsic pathway is triggered by the components 
which are already present in plasma. For the extrinsic pathway to occur, it requires 
exposure of tissue factors on the damaged cell wall. A clearer picture of caoagulation 
evolved over time. 
 
Intrinsic pathway 
Upon encountering a negatively charged surface such as a membrane, Factor XII 
(FXII) in the presence of cofactor High Molecular Weight Kininogen HMWK or HK gets 
activated to FXIIa. The letter “a” indicates that FXII has been activated. The minute 
amounts of FXIIa produced then use HMWK as an anchor to convert prekallikrein to 
kallikrien. Newly formed kallikrien acts as a positive feedback to accelerate FXIIa 
production. FXIIa then proteolytically cleaves FXI to form FXIa consecutively forming 
FIXa from FIX with HMWK as a cofactor. A complex called “tenase” consisting of 
FVIIIa, FIXa, Ca+2, and phospholipid membrane next converts FX to FXa. Finally, FXa 
with the help of cofactor FVa and in the presence of Ca+2 and phospholipid membrane 
forms a complex called “prothrombinase” which converts prothrombin (II) to thrombin 





The extrinsic pathway is initiated by the formation of a complex between FVII and 
TF (Tissue Factor). Tissue factor is a receptor for FVII and is located on cell surfaces. 
Whenever there is an injury to endothelium cells, FVII encounters TF and is 
nonproteolytically activated to FVIIa. Activated FVII proteolytically activates FIX, which 
accelerates the function of the tenase complex leading to the formation of FXa. With the 
formation of FXa, the prothrombinase complex is established leading to the formation of 
FIIa from FII. Biochemists have debated whether the extrinsic pathway is more 
physiologically relevant than the intrinsic pathway. Published results have provided 
evidence that even in the absence of FXII, the time taken for clot formation is not changed.  
Both the intrinsic and extrinsic pathways merge at a common point where FX is 
converted to FXa from the tenase complex. FXa is then the first factor to trigger the rest of 
the cascade. As mentioned earlier, FXa is a key component of the prothrombinase complex 
that is responsible for thrombin (FIIa) formation. The resultant serine protease thrombin 
converts freely flowing fibrinogen into a fibrin network. This fibrin network is later 
susceptible to proteolysis by plasmin. To maintain complete hemostasis, FIIa converts 
FXIII to FXIIIa, which covalently cross links fibrin monomers into a hard clot. 
Interestingly, the production of thrombin acts as a positive feedback by helping to activate 




















Modern blood coagulation and the importance of platelets 
None of the above-mentioned pathways indicated the importance of platelets. From 
1996 to 2001, several changes were made to generate a more general Modern Blood 
Coagulation Cascade (Figure 2).23  The updated viewpoint involved three steps: a) 
Initiation b) Amplification, and c) Propagation. The initiation step involves exposure of 
Tissue Factor (TF) on injured endothelium cells and formation of a complex between FVIIa 
and TF. This assembly leads to generation of minute amounts of FIXa and FXa. FXa on 
the TF bearing cell accumulates the prothrombinase complex components to convert 
prothrombin (II) to thrombin (IIa). Later in the amplification stage, the small amount of 
thrombin that is formed in the initiation stage activates platelets, thereby exposing receptors 
for clotting factors to adhere on to platelets. The activated platelets slowly expose FVa and 
Figure 1: Blood coagulation factors are shown as Roman numerals. The letter “a” after the Roman 
numerals denotes the active form of the factor. Other abbreviations include: HK-High Molecular Weight 
Kininogen, Ca-Calcium ion and PL-phospholipid. The common final pathway for both extrinsic and 
intrinsic pathways is the formation of Xa and Va. 
 




FVIIIa which leads to positive feedback for higher amounts of thrombin generation. 
Meanwhile, platelet adhesion starts to develop to initiate the propagation step. A burst of 
thrombin production occurs during the propagation step. TF bearing cells sequentially 
activate FIX, FX, FVIII, and FV leading to the formation of thrombin in higher amounts. 


























To control the growth of unwanted thrombi in normal vascular areas, the 
anticoagulant pathway is triggered. Three anticoagulants that terminate the coagulation 
cascade are antithrombin (ATIII), Protein C, and Protein S.25  ATIII in the presence of 
heparin inhibits the activities of serine proteases like FIIa, FIXa, FXa, FXIa, and FXIIa 
Figure 2: A) Initiation- TF on endothelium cell is exposed. FVIIa and TF interacts leading to the formation 
of IXa and Xa and minute amounts of FIIa. B) Amplification- Thrombin activates platelets, cofactors V and 
VIII and exposes various receptors on platelet surfaces. C) Propagation- platelet adhesion increases, factors 





Thrombomodulin (TM) when bound to endothelial cells accelerates the thrombin 
activation of Protein C by several thousand-fold. Protein C with the help of Protein S inhibit 
cofactors FVa and FVIIIa.26,27  Finally, Tissue Factor Pathway Inihibitor (TFPI) forms a 
complex with FXa and TF/FVIIa to hinder the start of the extrinsic pathway.   
 
Fibrinogen 
Fibrinogen (340 kDa) is an abundant glycoprotein composed of a dimer of 
nonidentical polypeptide chains (A, B and )2. This protein is 450 Å long and is held 
together with several disulfide linkages (Figure 3A).1,6  The fibrinogen dimer of trimers is 
sigmoidal in shape due to the following features. The N-termini of all six polypetides merge 
together to form a central globular “E” region. The C-termini of three chains meet at a point 
forming a globular “D”. This region is mainly composed of B and  chains.28,29  During 
fibrin formation, adjacent knobs in the “E” region make favorable contacts with the holes 
in the “D” region which increases the stability of fibrin. An interesting feature of the A 
chain is its C-terminus. It is a long flexible coiled-coil which ends with the C domain. 
The C regions (C-connector and C-domain) are not detected by X-ray crystallography 
and are considered as free-swimming appendages of fibrinogen. The C domains associate 
to form a dimeric domain near the central E region (Figure 3B).5,30  Fibrin clot stability 
and mechanical stiffness is improved when C is crosslinked by FXIIIa.31  This flexible 
C region is susceptible to lysis by the actions of plasmin.32 
Another interesting feature of fibrinogen is the presence of 11 Asparaginyl- linked 




however, desialidation resulted in the same rates of polymerization. Thus, it is the 






















The initial step of fibrin formation is triggered by the release of Fibrinopeptide A 
(FpA) by thrombin. Thrombin cleaves at the Arg16-Gly17 peptide bond of Fbg Aα, leading 









Figure 3: A) Fibrinogen ,  and  are represented in blue, green and red. The cartoon includes coiled-
coil connecting central E region and terminal D regions. Flexible C and carbohydrates not shown. This 
cartoon is generated in Pymol through PDB code 3GHG. B) Fibrin clot formation is initiated by the 
cleavage of FpA leading to the formation of protofibrils, next the cleavage of FpB results in lateral 
aggregation of fibrin. Finally, FXIIIa imparts isopeptide bonds between two fibrin molecules thereby 





Fibrinopeptide B (FpB) at the Arg14-Gly15 peptide bond. Release of these two N-terminal 
peptides within the central E region accelerates the lateral aggregation of fibrin (Figure 
3B).30  Activated FXIII (FXIIIa) is then responsible for the introduction of covalent -
glutamyl--lysine cross-links between the fibrin molecules.34,35  These cross links make the 
fibrin clot stiffer and less susceptible to fibrinolysis. Interactions observed in the crystal 
packing of human fibrinogen are end-to-end interactions between C domains, lateral 
antiparallel interactions between C, and antiparallel association of coiled-coil regions. A 
and B knobs of the central E region are buried in C and C holes.33,36 
Thrombin 
The serine protease thrombin is originally produced as the 72 kDa zymogen, 
Prothrombin (ProT). ProT is a Vitamin K-dependent protein composed of Fragment-1 (1-
155), Fragment-2 (156-271) and a protease domain (272-579). Fragment-1 contains a Gla 
domain (which contains 10 γ-carboxyglutamates) and disulfide containing Kringle-1. 
Fragment-2 contains a second disulfide containing Kringle-2, and the protease domain 
contains the A chain (272-320) and the catalytic B chain (321-579).37  ProT is 
physiologically activated by the prothrombinase complex consisting of the serine 
proteinase Factor Xa and the cofactor Factor Va, a phospholipid membrane, and Ca2+. ProT 
is anchored to the membrane surface through the Gla domain of Fragment 1 (F1). The 
membrane-associated prothrombinase complex can first be cleaved at ProT R320 leading 
to formation of an active intermediate Meizothrombin or cleavage at ProT R155 to form 
another inactive intermediate called Prethrombin-1 (PT1) (Figure 4). In platelets, cleavage 




Fragment 1.2 (Gla, Kringle 1, and Kringle 2). Subsequent cleavage at R320 gives rise to 
the active protease thrombin (36.7 kDa). (Figure 4, 5).38-40  Autolysis of α-thrombin 






























Figure 4: Schematic representation showing cleavages that occur in the conversion of 
prothrombin to meizothrombin or prethrombin-2 and then to thrombin. Autolysis leads to β- 
thrombin and then to γ-thrombin (Straight numbering is presented for β and γ- thrombin). 
Figure 5:  Surface structures of A) Prothrombin (4HZH), B) Prethrombin-2 (1MKX), C) Thrombin 
(1PPB). Active site is represented in yellow color. Anion Binding Exosite I and II are represented in 
green and blue colors. A-chain oriented in the back is in red, Autolysis Loop is in purple. All the structures 




α-thrombin is highly homologous to serine proteases such as trypsin and 
chymotrypsin with His 57, Asp 102 and Ser 195 (chymotrypsin numbering) forming the 
catalytic triad of the active site (Figure 6). Hydrolysis of the R-X or K-X substrate bond 
occurs by the mechanism shared with trypsin, chymotrypsin, and other serine proteases. 
This mechanism is shown in Figure 7. A nucleophilic attack of Ser 195 on the carbonyl 
atom of the scissile peptide bond initiates the reaction. As the carbonyl rearranges to give 
an acyl-enzyme intermediate, the new N-terminus of the hydrolyzed peptide chain is 
released. A water molecule enters the active site and participates in the reverse sequence, 
releasing the new C-terminus of the hydrolyzed substrate and regenerating the active 
enzyme.42,43 
Thrombin enzyme specificity is controlled through several loops including the 60s 
loop (or β insertion loop), autolysis loop (or γ loop), and the 220s loop (or Na+ binding 
loop) (Figure 6). The presence of prolines, tryptophans, and tyrosines in the β-insertion 
loop serves as a rigid hydrophobic cap over the active site and mediates contacts with the 
hydrophobic substrate residues N-terminal to the scissile bond.37  The autolysis loop is 
more hydrophilic and flexible in nature and makes contact with residues C-terminal to the 
active site thereby influencing the substrate specificity. A third important loop (220s loop) 
contains a site for Na+ binding, which controls the activities of thrombin and is important 
for considering allostery. Na+ bound thrombin is denoted as “fast” thrombin and whereas 
the Na+ free enzyme is denoted as “slow” thrombin. The chymotrypsin numbering is 
followed for thrombin.44-46  For example, the 9-residue insertion between thrombin residues 
60 and 61 is known as the Trp60s insertion loop. Residue 60 is followed by 60a, 60b, 60c, 



























Figure 6:  PDB structure of Thrombin (1PPB). Active site (His 57, Asp 102 and Ser 195) is 
represented in yellow color. Anion Binding Exosite I and II are represented in green and blue colors. 
A-chain oriented back is in red,60 Loop is in cyan, Autolysis Loop is in purple.  
Figure 7: The Serine Protease Mechanism. Product from second reaction is the acyl 




Apart from the insertion loops, thrombin specificity is also dictated by secondary 
anchoring sites called exosites. Anion Binding Exosites I and II are rich in positively 
charged residues and are located on the opposite sides of the active site.47,48  Residues from 
ABE-I include F34, K36, R67, R75, R77a, K81, K109, K110, and K149e. Ligands that 
bind to ABE- I include the Protease Activated Receptors PAR1 (49-62)49 and PAR3 (44-
56),50  and the leech derived thrombin inhibitor Hirudin (54-65).51  Residues from ABE-II 
include R93, R97, R101, R126, R173, R175, R233, K235, K236, and K240. Ligands 
binding to ABE-II include glycoprotein GpIbα (269-286),52  fibrinogen γ´(410-427),53 
another leech derived thrombin inhibitor Haemadin (45-57),54 and heparin.55  X-ray crystal 
structures shown below display the binding modes of PAR3 and GpIbα ligands to their 










Published literature supports the hypothesis that communication is possible 
between the exosites and with the catalytic center.56-59 Amide hydrogen/deuterium 
exchange coupled with mass spectrometry revealed that ligand binding at the exosites 
Figure 8:  Ligands bound to thrombin A) PAR3 (44-56) B) GpIbα (269-286), PDB structures 
include 1P8V for GpIbα and 2PUX for PAR3. Anion Binding Exosite I and II are represented 
in green and blue colors. GpIbα (269-286) is depicted in orange sticks, PAR3 (44-56) is depicted 
in blue sticks. 




promoted both local and long-range effects, but the ligands did not exhibit identical 
conformational changes to thrombin.60  When considering ABE I ligands, Hirudin could 
show local effects but PAR3 and PAR1 showed both local and long-range effects. Turning 
to ABE II ligands, GpIbα and fibrinogen γ´ could both show local and long-range effects.60 
The substrate amino acid sequence on the N-terminal side of the scissile bond 
makes significant contributions to thrombin binding and hydrolysis rates. The P 
nomenclature system (P3 P2P1P1'P2'P3') is used to assign the individual amino acid 
positions on the substrate peptides.61  The scissile bond is designated as P1-P1'
. The serine 
protease thrombin specifically cleaves after arginine or lysine residues located at the P1 
position. A deep active site cleft accommodates the positively charged side chains of R and 
K. Sequences of some thrombin substrates and an inhibitor are shown in Table 1.  
Table 1: Substrate sequences that target thrombin active site region.  indicates the 




Factor XIII (28-41) V34 AP                          28T V E L Q G V V P R G V N L41 
Fibrinogen Aα (7-20)                                    7D F L A E G G G V R G P R V20 
Fibrinogen Bβ (5-16)                            5D N E E G F F S A R G H 
PAR1 (29-45)      29K A T N A T L D P R S F L L45 
PAR4 (38-51)               38S T P S I L P A P R G Y P G51 
PPAck              D-F P R-ck 
________________________________________________________________________ 
Human sequences were taken from the following sources: PPAck is D-phe-Pro-Arg-chloromethylketone,37 
Factor XIII, 62 Fibrinogen Aα and Bβ chains,63 and thrombin receptors PAR164 and PAR465. 
 




Interactions between thrombin and PAR1 (38LDPR41) are shown in Figure 9. The 
Arg 41 residue at the P1 position forms a salt bridge with thrombin D189, Pro 40 at P2 
makes extensive IIa contacts (Y60a and W60d), P3 does not necessarily contact thrombin, 




















Fibrin-stabilizing factor: FXIIIa 
Transglutaminase FXIIIa is involved in crosslinking the fibrin monomers that are 
generated by thrombin cleavage of fibrinogen. The major crosslinking sites include the γ- 
γ and α-α contacts that are crucial for stabilizing the fibrin clot structure.  FXIIIa also 
crosslinks clot stabilizing proteins like α2-antiplasmin and Plasminogen Activator Inhibitor 
1 (PAI1) to protect the clot from premature lysis. Besides its role in blood coagulation, 
Figure 9: Thrombin receptor PAR1 segment 38LDPR41 bound to thrombin, PAR1 can 





FXIII has also been identified as an important enzyme in maintaining pregnancy, vascular 
permeability, bone biology, and wound healing.67  
In plasma, pFXIII exists as a hetero tetramer, consisting of two catalytic A subunits 
and two carrier B subunits (FXIIIA2B2) (Figure 10A).  The FXIII- A subunit contains an 
activation peptide- AP (1-37), a - sandwich domain (38-184), a catalytic domain (185-
515), and two -barrel domains (516-628, 629-731) (Figure 10B).68  V34L is a notable 
polymorphism within the AP region which seems to have cardioprotective functionality.69 
The FXIII- A subunit has 9 cysteine residues, and among them is Cys314 a key residue of 
the catalytic traid. C314, along with H373 and D396, form the FXIII active site. The Cys 
314 residue is protected from the solvent by the FXIII AP. This thiol amino acid is also 
hydrogen bonded with Tyr 560. None of the 9 cysteine residues form disulfide linkages. 
Arg260 of one FXIII monomer is involved in a salt bridge with Asp404 of another 
monomer. Asp 11 of one FXIII AP forms a salt bridge with Asp 343 on the opposite 
monomer, thereby demonstrating how the AP of FXIII covers the active site. The FXIII-B 
subunit is a glycoprotein consisting of 10 sushi domains held together by disulfide bonds. 
The FXIII B subunits protect the catalytic FXIII A2 from degradation and premature 
activation.70,71  
During the activation of plasma FXIII A2B2, thrombin first cleaves the FXIII A2 
activation peptides between Arg37-Gly38. In the presence of Ca+2 ions, the regulatory/ 
carrier FXIII- B subunits dissociate from FXIII-A. The resultant FXIII-A subunits undergo 
conformational change to create active FXIIIa. In the cellular form found in platelets, 
cFXIII is only a dimer of A subunits. cFXIII can be activated by thrombin in the presence 




analytical ultracentrifugation (AUC) and size-exclusion chromatography studies revealed 






































Figure 10: A) structure of cellular FXIII A2 subunit rendered in surface model. Catalytic domain shown 
in light turquoise, - sandwich is in blue, -  barrel 1 and 2 shown in light and dark green colors. B) 
structure of cellular FXIII A2 subunit rendered in ribbon model. Catalytic domain shown in light 
turquoise, - sandwich is in blue, - barrel 1 and 2 shown in light and dark green colors. Other A monomer 
is shown in grey. Structure was generated with Pymol using PDB code 1GGU. 
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High mM Ca+2 
 
      90º flip 
 
A  B  
Figure 11: A) structure of catalytic A2 subunit. Catalytic domain shown in light turquoise, - sandwich is 
in blue, -  barrel 1 and 2 shown in light and dark green colors. Other A monomer is shown in grey. B) 
Conversion of inactive FXIIIA2 to FXIIIa in the presence of high mM (40 mM) Ca+2 ion. Structure was 





To form the platelet plug during vascular injury, several receptors are involved in 
platelet adhesion. GpIbα is an important platelet adhesion receptor that belongs to the 
leucine-rich repeat family. Before the thrombin burst is generated, GpIbα binds to von 
Willebrand factor on the endothelial cells lining the vasculature which accelerates platelet 
activation. Activated platelets expose the procoagulant/ negatively-charged phospholipids 
for attracting several coagulation factors to trigger the blood coagulation cascade.74-76  
Other important ligands of this receptor include thrombin, FXIa, FXIIa, and High 
Molecular Weight Kininogen (HMWK). By interacting with these ligands, GpIbα plays an 
important role in maintaining hemostasis. This glycoprotein also contributes a role in 
inflammation through leukocyte recruitment to fight infection. The absence or low 
expression of GpIbα leads to a severe bleeding disorder called Bernard-Soulier 
syndrome.75,77  There are two unique features of the GpIbα receptor. The N-terminus (1-
267) has the Leucine-Rich repeat (LRR) which is responsible for curvature of the protein, 
whereas the C-terminus has a highly anionic cluster (269- 286) that is responsible for 
binding several clotting factors (Figure 12A and B) including thrombin.52 
The present research mainly focuses on interactions of GpIbα (269-286) with 
thrombin. The C-terminal region of the N-terminal fragment (1-290) is rich in anionic 
residues (269DEGDTDLYSDYSYSPEEDTEGD
287) and includes three sulfated tyrosines. In 
biochemical studies, the sulfated tyrosines are often replaced with phosphorylated 
tyrosines. X-ray, solution NMR, and HDX-MS studies proved that the anionic cluster of 
GpIbα (269-286) binds to ABE II of thrombin.78,79  Through HDX-MS studies, Malovichko 




thrombin ABE II and can allow for inter-exosite communication over to ABE I.60 
Additional studies demonstrated that the presence of GpIbα increases thrombin- catalyzed 
hydrolysis of PAR1 (38-60). Such results provide evidence that binding of GpIbα (269-
















Protease Activated Receptors (PARs) 
 Platelets play an important role in hemostasis, inflammation, angiogenesis, and 
cancer metastasis. At the site of vascular injury, platelet accumulation, activation, and 
aggregation are quite essential to prevent major blood loss. Platelet activation can be 
mediated through the small family of G-protein coupled Protease Activated Receptors 
PARs. PAR1, PAR2, PAR3, and PAR4 have been identified. PAR1, PAR3, and PAR4 are 
activated by thrombin whereas PAR2 is activated by trypsin, FVIIa, and FXa.64,81,82  
Figure 12: A) Ribbon structure of GpIbα (1-267). N-terminus is in blue, LRR is in green, and 
C-terminus is in purple. B) von-Willebrand factor shown in cyan (478- 705) is complexed at the 
C-terminus region. Structures were generated with Pymol using PDB codes 1MOZ and 1M10. 




Human platelets use PAR1 and PAR4 to trigger platelet secretion and aggregation. In 
contrast, murine platelets express PAR3 and PAR4 for platelet activation and 
accumulation. In humans PAR3 is known to play a regulatory role in megakaryocytic and 
endothelial cell development.83 
Thrombin cleaves the N-terminal extracellular domain of PARs at a specific R-X 
peptide bond leading to the formation of a tethered ligand which intramolecularly binds to 
the body of the receptor to elicit transmembrane signaling (Figure 13).82  However, the 

























Figure 13: Mechanism of activation of PAR1. Thrombin is visualized as green sphere, identifying N-
terminal exodomain. Thrombin cleaves at R41-S42 to produce a new tethered ligand to elicit 
transmembrane signaling. Picture was adapted from Coughlin, S.R (2000).  
IIa 





h PAR1         ARRPESKATNATLDPRSFLLRNPNDKYEPF-WEDEE-------- 
m PAR1       MSQPESERTDATVNPRSFFLRNPSENTFELVPLGDEEEEE 
h PAR3         MENDTNNLAKPTLPIKTFRGAPPN---SFEEFPFSALE------ 
m PAR3        GINVSDNSAKPTLTIKSFNGGPQN----TFEEFPLSDIE------- 
Hirudin                              TGEGTPKPQSH----NDGDFEEIP-EEYLQ 
 ׀                 
        
                                                                                Hir      WEDEE
30                                40                            50                                 60                 
              60    
Thrombin cleavage site 
SO42- 
 
Figure 14: Sequence comparison between human and murine versions of PARs. Picture shows the 





Located beyond the thrombin cleavage sites, PAR1 and PAR3 both contain hirudin-
like sequences.49,50,84,85 Hirudin is a leech derived inhibitor that utilizes a DFEEI sequence 
to anchor on to thrombin ABE I. Human and murine versions of PAR1 and PAR3 also 
contain segments with highly anionic residues (51KYEPF55 in PAR1 and 46TFEEF50 in 
PAR3) that target ABE I (Figure 14).84  These residues help increase the affinities of PAR1 
and PAR3 for thrombin. PAR1 is the best substrate for thrombin in terms of kcat/Km. In 
murine models, PAR3 acts as cofactor for PAR4 activation at low thrombin concentration. 
PAR3 has been documented to dimerize with PAR4 for further transmembrane signaling.86 
 
Physiological relevance and research goals 
25% of deaths worldwide are due to ischaemic heart disease and strokes. Being a 
global disease burden, this health issue attracted many biochemists to decipher the 
mechanism involved in hemostasis.87  Hemostasis is an important physiological process to 
control the unwanted loss of blood during trauma. The three-step process begins with 
vasoconstriction of the blood vessel. Next, platelet plug formation to reduce the gap and 
minimize the blood flow occurs. The last and most important step involves the 30 important 
biomolecules that are part of the blood coagulation cascade.88,89  The coagulation factors 
and cofactors work together to convert the liquid blood to an insoluble fibrin network 
which is less susceptible to lysis.30  Imbalances in the blood coagulation pathway may lead 
to deleterious effects like stroke, heart attacks, and pulmonary embolism. To control the 
unwanted formation of blood clots, anticoagulation events are in place. Key features about 
blood coagulation including the various factors involved in coagulation and 




are administered to the patients when the physiological levels of natural anticoagulants are 
not enough to elicit their functions. Several anticoagulant drugs have been developed and 
new generation versions have been developed in recent years. Some intriguing therapeutic 
strategies are currently being developed to reduce the side effects of anticoagulants and to 
actually reverse the anticoagulation event.90 
 A few blood coagulation factors utilize a Gla domain to anchor on to a phospholipid 
membrane. This Gla domain contains the specialized amino acid γ-carboxy glutamate that 
is generated with the help of Vitamin K. Vitamin K antagonists acts as competitive 
inhibitors, hindering the the formation of the Gla residue and thus hindering zymogen 
activation. Dicoumarol and its synthetic analog Warfarin are the most famous Vitamin K 
antagonists. They inhibit the redox step of the Vitamin K cycle and hamper the generation 
of vitamin K, and thus induce their anticoagulation activity. A well-known side effect in 
patients administered Vitamin K antagonists is excessive bleeding.91  
Heparin is another anticoagulant that is administered to patients with cardiovascular 
abnormalities. Heparin is known to promote conformational changes to Antithrombin III. 
The properly oriented antithrombin-heparin complex then binds to factors Xa and IIa to 
hinder their serine protease activities. However, heparin induces thrombocytopenia and  
dysfunction of  platelet activation. Heparin is also known to have non-specific plasma 
binding effects. Because of these concerns, research slowly shifted towards targeting 
specific factors and binding sites in blood coagulation.92 
Factor X is a common factor of both the intrinsic and extrinsic pathways and is 
involved in activating the final serine protease thrombin. As a result, several drugs are 




Fondaparinux, Rivaroxaban, Apixaban, and Endoxaban. These drugs work more 
efficiently than Vitamin K antagonists and heparin and have fewer side effects. However, 
a critical issue concerned with FXa inhibitors is the lack of an antidote to reverse the 
anticoagulant activity.93 
Since thrombin is known to have more than a dozen substrates that are involved in 
both coagulation and anticoagulation, extensive time has been dedicated toward 
developing direct thrombin inhibitors. Three types of direct thrombin inhibitors are 
available on the market. The first type is the univalent inhibitor which binds to the thrombin 
active site and includes drugs like Argatroban, Melagatran, and Dabigatran. Like FXa 
inhibitors, such IIa inhibitors do not have a universal antidote to reverse the anticoagulant 
effect.94  Also, univalent inhibitors lead to coagulopathy. The second inhibitor type is the 
bivalent inhibitor where the drugs take advantage of ABE I in addition to the active site to 
improve affinity with thrombin. Bivalirudin is known to bind reversibly to thrombin and 
bridge both the ABE I and the active site.95  However, the half-life of bivalirudin is low 
due to spontaneous chemical degradation by proteases in the body.  
Allosteric inhibitors are the third class of direct thrombin inhibitors and include 
DNA96 and RNA aptamers,97 benzofuran dimers, benzofuran trimers, and heparin based 
analogs.98  These molecules take advantage of ABE I, ABE II, and the sodium ion binding 
loop. The best DNA aptamers are selected from a pool of nucleic acids through a technique 
called “SELEX” (systematic evolution of ligands by exponential enrichment) to elicit the 
anticoagulation activity.99  The SELEX approach is still evolving and might take several 
decades to make a “druggable” form. Meanwhile, a non-enzymatic protein called 




blocks the thrombin activation.100,101  This venom protein is also known to compete with 
ProT F2. Such an effect would indicate that bothrojaracin can also bind to ABE II of 
thrombin. However, bothrojaracin is known for its toxicity.  
A few antagonists targeting the physiological substrate ligands have also been 
developed. PAR targeted therapy is taking shape to inhibit PAR activation and platelet 
aggregation. RWJ-56110 acts as antagonist to PARs which not only blocks platelet 
aggregation but also hinders PAR1 and PAR4 dimerization responsible for several 
signaling events.102,103 
Keeping these different anticoagulant functionalities in mind, researchers will want 
to develop future drug candidates that regulate hemostasis with fewer side effects and 
enable reversal of their functionalities with effective antidotes. Considering this big picture 
and the use of (pro)thrombin as the drug target, we wanted to better understand the 
conformational changes of the active site region and the (pro)-ABEs of (pro)thrombin that 
lead to different physiological processes. Understanding different conformations of 
biomolecules can help develop novel therapeutics that target specific hot spots on 
(pro)thrombin. Also, binding affinities between the drug and its binding partner plays a key 
role in improving the efficacy. Probing the binding affinities of individual residues within 
the physiological peptide ligand will be a big asset for developing better therapeutics. 
Hence, the dissertation is divided into the following chapters. Chapter 2 mainly 
focuses on different techniques employed in this research and includes the theory behind 
1D proton line broadening, 2D TOCSY, 2D tr-NOESY, and 2D HSQC. These solution 
based techniques are used as complementary methods to X-ray crystallography to evaluate 




the principle behind ITC (Isothermal Titration Calorimetry) is explained as it is used as a 
supplementary technique to evaluate the global KDs between two binding partners. Chapter 
3 then emphasizes on how a PAR based ligand (PAR3) probes exosite maturation at single 
amino acid levels. This chapter will also include the quantitative measurements of binding 
affinities of 15N- labeled PAR3 amino acids towards zymogen ProT vs mature thrombin. 
As a continuation of this study, Chapter 4 discusses the comparative studies between the 
binding affinities of two PAR based ligands (PAR1 and PAR3) towards (pro)-exosites. The 
most striking segment in this chapter is further proof of allosteric communication between 
exosites ABE I and ABE II. Chapter 5 describes the thrombin catalyzed hydrolysis of Fbg 
Bβ (5-16) and compares the kinetic parameters with common substrates of thrombin. In 
addition, 1D and 2D solution NMR results are used to explain secondary structural 
information for the thrombin bound FpB (5-14) and the weak kinetics associated with 
thrombin- catalyzed release of FpB (5-14). As a wrap up, Chapter 6 includes a summary 
of all the different research projects, some new preliminary results attained so far, and 


















NUCLEAR MAGENTIC RESONANCE (NMR) 
Nuclear Magnetic Resonance (NMR) examines the magnetic properties of such 
nuclei as the proton (1H), the carbon 13 isotope of carbon, and the nitrogen 15 isotope of 
nitrogen. Unlike some other biophysical methods, NMR is a non-destructive technique 
which enables us to deduce the positions of the nuclei within the molecule, identify 
different types of environments, and assess the types of atoms within the molecule.104 
 Any charged particle that spins behaves like a tiny bar magnet, and it generates 
a magnetic field. The proton in the hydrogen atom being a charged particle also behaves as 
a tiny magnet, generating its own magnetic field. In the presence of an external magnetic 
field, the spin ½ proton can adopt two orientations with respect to the applied magnetic 
field. One is the lower energy state where it aligns with the magnetic field, and the other is 
the higher energy state, opposing the magnetic field. The spinning proton can move under 
the influence of the external magnetic field. A spinning proton can be considered as a 
spinning top. If the spinning axis is not parallel to the applied magnetic field it will precess 
around the axis of the external field (Figure 15). The precessional frequency ν, is directly 
proportional to the strength of the external magnetic field B0. When nuclei are irradiated 




axis is tilted away from the axis of B0. If the radio frequency field is pulsed on for a time 
such that the spinning axis and the magnetic field axis are perpendicular, the pulse is known 










                                                 
ν ∝ B0                                               (1a) 
𝜈 =  
 𝛾𝐵0
2𝛱
                                  (1b) 
 
γ is the gyromagnetic ratio between the nuclear magnetic moment μ and the nuclear angular 
momentum I. The ν values for a few magnetic nuclei with different field strengths is given 
in Table 2.105 
Table 2: Precessional frequencies (in MHz) as a function of field strength (Tesla).105 
       B0 (Tesla)        1.4          1.9          2.3        4.7          7.1       11.7    14.1 
________________________________________________________________________ 
         Nucleus 
                 1H              60            80        100        200        300       500      600 
                2H                 9.2         12.3      15.3       30.6        46.0      76.8     92 
               13C              15.1          20.1      25.1      50.3        75.5    125.7    151 
              15N                 6.1           8.1      10.1      20.3        30.4      50.7      61 
              19F               56.5          75.3      94.1    188.2      288.2    470.5    565 







ΔE = hν 





When the nuclei precess, they emit radiowaves, which can be recorded by a 
radiofrequency detector. However, there can be two types of radiationless mechanisms for 
a high-energy state nucleus to lose (relax) energy.104  The first type of relaxation is the 
spin-lattice relaxation or longitudinal relaxation with time constant T1.  In this process, the 
nuclei transfer energy to the surrounding lattice.  Surrounding molecules can be from the 
solvent or from the same molecule. The second type of relaxation is spin-spin relaxation 
or transverse relaxation with time constant T2. Here, the energy is transferred to 
neighboring nuclei. In this mechanism, one nucleus loses energy whereas another nucleus 
gains energy and hence both nuclei are coupled. In protons, spin-spin relaxation is the 
predominant way for radiationless energy transfer.105 
Molecular weight plays an important role in dipolar coupling. The rotational 
correlational time (τc) is the time required for a molecule to rotate 1 radian, which is 
proportional to the size of a protein and the viscosity of the solution. τc is 1nsec /2.6 kDa 
of protein mass at T= 300 K. Thus, a smaller protein can fluctuate/tumble (ωτc <<1) more 
rapidly than a larger protein (ωτc >>1), where a is the radius of the protein, and η is the 
viscosity 
         𝜏𝑐 =
4𝛱𝜂𝑎3
3𝑘𝑇
                            (2) 
The rates of relaxation are important. They determine the width of the NMR peaks. 
If both T1 and T2 are small, the lifetime of the high energy nucleus is short and will lead to 
broad spectral lines.  If both T1 and T2 are large, then sharp spectral lines can be seen. The 
uncertainty principle can give us a qualitative relation between relaxation time and 




(frequency) must be small, which means the frequency spread is small thus leading to 
narrow lines. By contrast, if Δt is small, the large Δν will result in large spread of 
frequency.105 
𝛥𝐸 ∗ 𝛥𝑡 ~
ℎ
2𝛱
                         (3a) 
as E = hν                               (3b)  
                                                           𝛥𝜈 ∗ 𝛥𝑡 ~
1
2𝜫
                          (3c) 
 
Proteins in solution are highly dynamic. Folded proteins reorient due to rotational 
diffusion. In addition, proteins can have internal degrees of flexibility. Different 
conformations can lead to different protein functions. A protein can be defined as an 
ensemble of different conformations that sample between various spatial and temporal 
scales ranging from nanometers to micrometers and femtoseconds to hours. In short, 
proteins are highly “dynamic molecules”. NMR provides the greatest advantage to study 
different structural changes ranging from bond breakage/formation to domain motions 
which fall within a time scale from 10-15 secs to 103 secs. Figure 16 provides a range of 






























Bond vibration/ Side chain 
rotation/ Loop motion/ 
Molecular tumbling 
Domain motion 
Figure 16: Protein conformational changes over a broad range of timescales. Adapted 





The remainder of this chapter focuses on 2D TOCSY, 2D tr-NOESY, and 2D 
HSQC experiments and how these NMR techniques can be used to obtain structural 
information about a protein or the ligand. Any 2D NMR experiment requires four essential 
steps. The first step is recovery, during which spins return to equilibrium. This phase 
typically ranges from 0.5-5.0 secs. Exciting the first spin type (let suppose A) by applying 
a single 90º pulse will end this phase. The second phase is the evolution period (t1) which 
can encode the chemical shift of A. This period measures the A chemical shift indirectly 
i.e., it is not directly detected by the receiver coil. This evolution phase ranges from 0-5 
secs. In the third phase, the magnetization of A spins is transferred to coupled B spins. The 
coupling is either J-coupling or dipolar coupling. The fourth and final phase is the detection 
period, where the FID of B spins is observed directly. This period ranges from 50-200 ms. 
These four steps are typically repeated 2 to 32 times to increase the signal to noise ratio  





2D TOCSY (Total Correlation Spectroscopy) 
 2D TOCSY is used to identify networks of spins that are scalar coupled. 
Spectra from this homonuclear experiment reveal the cross peaks between spins which are 
connected by bonds. The TOCSY pulse sequence involves a 90º pulse in the beginning, a 
frequency labeling time t1, followed by series of 180º (∏) pulses during which scalar 
coupled spins exchange magnetization. This pulse sequence is then followed by detection 
t1 t
         Evolution                                Detection 
         Preparation                                Mixing 




of the FID. 2D transformation of the data table shows both diagonal and off diagonal peaks. 








Consider three different spins, A, B, and C. If spin A is coupled with spin B, and 
spin B is coupled with spin C, then in the TOCSY spectrum one can see a cross peak 
between A and C, even though there is no direct coupling between these two spins. In 
Figure 19, black peaks correspond to cross-peaks between spins A and B due to 3J coupling, 
orange peaks correspond to cross-peaks between spins B and C due to 3J coupling, grey 
peak correspond to cross- peaks between spins A and C. Cross-peaks between A and C are 
due to an unbroken chain of couplings. Green peaks on the diagonal indicate that they are 
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Figure 19: Schematic TOCSY spectrum for the three spins. 
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Figure 18. Pulse sequence of 2D TOCSY experiment. 
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2D tr-NOESY (2D transferred nuclear overhauser enhancement spectroscopy) 
Nuclear spins also interact through space via dipolar coupling making it possible to 
learn interesting structural information about a biomolecule. The magnitude of the dipolar 
coupling depends on the strength of the magnetic field generated by one spin and the 
magnetic moment of the other spin. If the cross-peak is seen between two dipolar coupled 
spins which are spatially interacting, then it leads to the nuclear Overhauser effect and the 
peak is referred to as an NOE. The NOE intensity is related to the distance “r” between 
between two coupled spins which can be derived with the following equation. Ideally if 
two spatially interacting protons are separated by a distance of less than 5 Å, then a NOE 
can be observed.108  
             𝑁𝑂𝐸 ∝
1
<r6>
∗ 𝑓 (𝜏𝑐)                           (4) 
In the pulse sequence of an NOE experiment, a 90º-t1-90º pulse is used to frequency 
label the spins and return the magnetization to the z-axis. Subsequently, dipolar coupled 
exchange longitudinal magnetization occurs during the τm phase. The observed transverse 
relaxation time is created by the final 90º pulse. Like the TOCSY experiment, 2D 
transformation of the data table shows both diagonal and off diagonal peaks. Here, the off-
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For 2D tr-NOESY experiments, protein-ligand complexes are examined that 
contain less than stoichiometric amounts of a large binding protein. A free peptide ligand 
of up to 20 amino acids can tumble very fast in solution due to the absence of 
conformational restraints. This property results in ωτc ≤1 and longer transverse relaxation 
(T2) time. The 1D proton spectrum displays very sharp peaks and the 2D tr-NOESY will 
have very few NOEs. Once the peptide binds to the protein, the conformations accessible 
to the ligand become restricted by the geometry of the binding protein partner, and the 
peptide becomes part of a larger protein-ligand complex. The peptide may also adopt some 
secondary structure. These properties result in an increase in correlation time ωτc >> 1 and 
a shorter T2 time. As a result, many NOEs (Figure 21)109-112  can be observed. 
Intramolecular NOEs for the bound state of the peptide can be observed. 
 The use of 2D tr-NOESY for structural determination is based upon the assumption 
that the ligand is under fast exchange conditions (higher kon and koff rates from the protein 
surface). For a typical 2D tr-NOESY experiment, 10:1 ligand to protein ratios are preferred 
to increase the exchange rates. Increased exchange rates will make it possible for the 
peptide to associate and dissociate at least a few times during the NOE mixing time. During 
this time, NOE information is transferred from the bound to the free state. Typically, a 100-
200 ms mixing time is employed to obtain sufficiently intense cross peaks that can be 
correlated to inter- proton distances. If the ligand has relatively low exchange rates, then 
changes to pH, ionic strength, or temperature can alter the exchange rates to enable the tr-
NOESY experiments to reveal more productive information. Other modifications that can 




amidation of a C-terminal carboxyl group. Individual amino acid substitution within a 












Ligand Binding Kinetics 
Studying enzyme-ligand interactions through NMR is achieved through observing 
the changes in chemical shift with respect to changing either protein or ligand 
concentrations. These types of chemical shift changes fall under three regimes- fast, 
intermediate, and slow exchange (Fig 22). For the fast exchange regime (kex >> |∆ω|), only 
one signal is observed reflecting the population-weighted averages of chemical shift, 
intensity, and linewidth. For the intermediate exchange regime (kex ≈ |∆ω|), only one signal 
with anomalous peak broadening and an intermediate chemical shift is seen. Finally, for 
slow exchange regime (kex << |∆ω|), signals from both states are observed reflecting their 
distinct chemical shifts, intensities, and line widths. ∆ω = ωP – ωPL, where ∆ω is the change 




in resonance frequencies of nuclear spins calculated as a difference between the resonance 
frequencies of free (ωP) and bound (ωPL) (Figure 22).106,111 
 















The chemical shifts of homonuclear spins mostly overlap. To detect the correlation 
between protons and their attached heteronuclear spins, heteronuclear J-correlated 
spectroscopy is employed. HMQC (Heteronuclear Multiple-Quantum Coherence) and 
HSQC (Heteronuclear Single- Quantum Coherence) are two methodologies that provide 
this type of information. Our research has mainly employed 2D- HSQC to examine protons 
that are directly attached to particular nitrogens or carbons. The HSQC pulse sequence 
involves the transfer of magnetization from 1H to usually 15N or 13C through INEPT 
(insensitive nuclei enhanced by polarization transfer). After a time delay of t1, the 
kex = kon [L] + koff                       (6) 
 
Fast   exchange                         Intermediate exchange                    Slow exchange 
 
Free                    Bound                               Free          Bound                             Free           Bound                   
Bound          
Figure 22: Three different exchange regimes: Fast, Intermediate, and Slow regimes in 2D 




magnetization is transferred back to the proton through the retro-INEPT step. The 1H signal 
is detected in the direct dimension, and the heteroatom 15N or 13C is detected in the indirect 









Chemical shift peturbations (CSP) reflect the changes in chemical shift that occur to a 
ligand or protein when the binding partner is added. These CSP provide a tremendous 
wealth of information about the environment of the binding site, the binding affinity, and/or 
possible structural features of the complex. For the current research, one use of CSP was 
to calculate the binding affinities between the ligand and the protein. CSP can be recorded 
for different nuclei like protons (1H), 13C, and 15N. The CSP for 1H are affected by several 
factors including paramagnetic effects, magnetic anisotropy around bonds, aromatic ring 
currents, and electrostatic field effects. Carbons are mainly affected by local dihedral 
angles. Nitrogens and carbonyl groups depend on hydrogen bonding and on the identity 
and side chain conformation of the preceding amino acid.113  
CSP can be an asset in determining weak binding affinities if the protein-ligand kinetics 
fall under the fast exchange regime. Under such conditions, there are often enough titration 
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points in the Δobs versus the protein/ligand concentration plot to approach saturation and 
thus obtain a more accurate KD value. Binding affinities are calculated using the equation 
shown below, where KD is binding affinity, [L0] is the ligand concentration, [P0] is the total 
protein concentration, and Δobs is the CSP between the free and bound form.
106 
       Δobs = Δmax ∗
(KD+[L0 ]+[P0 ])−√(KD+[L0 ]+[P0 ])2  −(4[P0 ][L0 ])
2[P0 ]
                      (7) 
ISOTHERMAL TITRATION CALORIMETRY (ITC) 
        Interactions between a series of biological molecules can lead to important biological 
processes like immune response, signal transduction, and gene expression. It is therefore 
important to know the nature of forces that help in stabilizing the individual interactions. 
Isothermal Titration Calorimetry (ITC) is an excellent biophysical technique which not 
only gives binding affinities KD but also gives information about the thermodynamic 
parameters like free energy of binding (ΔG), enthalpy of binding (ΔH) , and stoichiometry 
(n). The entropy of the system (ΔS) can be calculated from the well- known Gibbs 
fundamental equation (Figure 24).114 
    ΔG = - RT ln Ka                                                         (8a) 
    ΔG = ΔH – TΔS       (8b)  
 
     
 
       
 
       
 




         An ITC instrument consists of two identical cells composed of a highly efficient 
thermal conducting material, mostly hasteloy or gold, that is surrounded by an adiabatic 
jacket. A sensitive thermopile/thermocouple detects the temperature differences between 
the two cells and between the cells and the jacket. Heaters in both cells are activated when 
there is a temperature difference between the cells. Furthermore, these heaters seek to 
maintain identical temperatures between the two cells (Figure 25). In a typical ITC 
experiment, the macromolecule is placed in the sample cell, whereas the reference cell has 
either water or buffer. During the experiment, titrant will be injected into the sample cell, 
and based upon the type of association, heat will be evolved or taken up. If the association 
is exothermic, temperature of the sample cell will increase, and for an endothermic 
reaction, the temperature will decrease. Over the course of an ITC experiment, there is a 










The isothermal titration calorimeter is an extremely sensitive instrument and utmost 
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isotherm can be characterized by a unitless value c (wiseman parameter), which is the 
product of the association constant Ka, the macromolecular concentration [M], and the 
stoichiometry n (Figure 26).117  A large c is seen for complexes where saturation is 
achieved already at 2 or 3 injections of ligand. A smaller c occurs when the characteristic 
sigmoidal curve is completely lost. For a single-site binding model, a c value between 10 
and 500 is said to be optimal for curve fitting.118  The fitting process is erroneous if c < 10, 
and finally it said to be not feasible if c < 1. For accurate measurements of affinities and 
thermodynamic parameters 10 ≤ c ≤ 500 is preferable. 

























Figure 26: Dependence of ITC binding curve on c value. Picture adapted from 





DECIPHERING CONFORMATIONAL CHANGES ASSOCIATED WITH THE 
MATURATION OF THROMBIN ANION BINDING EXOSITE I 
 
INTRODUCTION 
Thrombin (factor IIa) is a multifunctional enzyme that plays critical roles associated 
with procoagulation and anticoagulation.  Procoagulant functions of thrombin include 
activating other coagulation proteins (zymogen factors V, VIII, and XIII), converting 
fibrinogen into fibrin that then polymerizes into a blood clot, and helping to activate 
platelets by cleaving the protease-activated receptors (PARs).  An important anticoagulant 
function of thrombin is to activate protein C and thereby help inhibit a set of coagulant 
proteins.47 
Thrombin also has two anion binding exosites, ABE I and ABE II, located on 
opposite sides of the serine protease active site (Figure 27A). These exosites have been 
shown to direct substrates to the active site, contribute to opening of the active site region, 
and help in attracting other regulatory molecules. Direct allosteric linkage may exist 
between ABE I and ABE II to modulate thrombin activity.60 
Thrombin is expressed as the zymogen Prothrombin (ProT) (Figure 27B).38,119  As 
ProT is proteolytically converted to thrombin, the immature pro-ABEs develop into the 




by the kringle-containing Fragment 1.2 (F1.2). This pro-ABE II region becomes exposed 
during the cleavage and activation process.38,120,121  By contrast, the pro-ABE I region is 
not directly affected by a cleavage event. Instead, subsequent conformational changes 











Designing new therapeutic anticoagulants that are directed toward individual 
thrombin exosites is a promising area of investigation.98,123,124  Different segments of the 
mature exosite surfaces could be targeted without directly occluding the active site with a 
small molecule. Unexpectedly, there are reports that ABE I - directed ligands based on 
Figure 27: Crystal structures of thrombin [Protein Data Bank (PDB) entry 1PPB] and prothrombin 
(PDB entry 4HZH). A) Ribbon diagram of thrombin in which the catalytic triad (His 57, Asp 102, and 
Ser 195) is colored yellow, (Pro)- ABE I is colored green, (Pro)- ABE II is colored blue, the autolysis 
Loop is colored purple, the 60s Loop is colored cyan, and the A chain is colored red. B) Space filling 
model of zymogen prothrombin missing the Gla domain. Kringles 1 and 2 are colored orange.  The 
other colored regions match those shown in panel A. C) Thrombin is generated from prothrombin 
following cleavages after Arg 271 and Arg 320.   The space filling model highlights the removal of 
the kringles (orange), the exposure of the active site (yellow), and full maturation of ABE I (green) 





hirudin 125,126 and DNA/RNA aptamers 127,128 can already bind to the immature pro-ABE I 
on ProT.  
Similar to hirudin and the aptamers, PAR3 also contains a binding region directed 
to thrombin ABE I.50   PARs are members of the G protein-coupled receptor family and 
are involved in platelet activation129 vascular remodeling, and vascular permeability.130  A 
fragment of PAR3 including amino acid residues 44QNTFEEFPLSDIE56 has been 
confirmed to bind in a specific manner to thrombin ABE I by X-ray crystallography.50  A 
review of the crystal structure reveals that thrombin residues located < 4 Å from the PAR3 
include F34, L65, R75, Y76, R77a, I82, and K110.  Chymotrypsin numbering is used to 
define the thrombin sequence. Thrombin R77a is an extra amino acid residue located after 










Figure 28: Crystal structure of thrombin in complex with murine PAR3 fragment (44-56).  The 
thrombin surface is rendered as gray ribbons and the PAR3 peptide as blue sticks.  Thrombin 
ABE-I residues that are located < 4 Å from PAR3 (44-56) are displayed as green ribbons or 
green sticks.  The PAR3 residues later chosen for 15N-HSQC titration studies include acidic 





The PAR3 (44-56) sequence is similar to the ABE I-directed region found within 
the leech-derived inhibitor hirudin (Figure 28).51  PAR3 could thus be a valuable new 
system for helping decipher the specific conformational changes that occur as pro-ABE I 
on prothrombin matures to ABE I on thrombin.  An examination of the X-ray crystal 
structures of prothrombin,120 thrombin-PAR3,50 and active site -inhibited PPACK-
thrombin37 reveals no striking differences between their pro-ABE I and ABE I regions 









The backbone root-mean-square deviation131 values for these three anion binding 
exosite regions were <0.8 Å. These values indicate that conformational changes may have 
been missed by crystallographic studies and are transient in nature. Nuclear magnetic 
resonance (NMR) could thus provide a critical alternative strategy for directly monitoring 
exosite maturation. To achieve this goal, we have performed NMR titration projects 
Figure 29: Structural alignment of the ABE I regions of prothrombin (PDB entry 4HZH), thrombin-
PAR3 (PDB entry 2PUX), and PPACK-thrombin (PDB entry 1PPB).  Regions encompassing exosite 
I (residues F34-M84, thrombin straight numbering) were selected, and then a backbone alignment was 
performed using MolMol. The backbone ABE 1 root-mean-square deviation values for the different 
protein -protein comparisons were then determined: 0.79 Å for ProT and thrombin-PAR3, 0.47Å for 
PPACK-thrombin and thrombin-PAR3 and 0.63 Å for ProT and PPACK-thrombin. This analysis 





comparing the binding of PAR3 amino acid residues (44-56) to the original zymogen state 
ProT versus the final active protease thrombin.  For the first time, the ability of the PAR3 
fragment (44-56) to target the immature (pro)-ABE I site on ProT could be explored.   
Previous hydrogen-deuterium exchange studies coupled with mass spectrometry 
(HDX-MS) demonstrated that regions of pro-ABE I experience increases in their level of 
solvent exposure as ProT is converted to thrombin.39  These exposures are hypothesized to 
be part of the exosite maturation process. NMR removes the issue of only probing segments 
of a protein and would allow for single -amino acid residue analysis.  Moreover, NMR has 
the unique advantage of allowing KD measurements in solution at this individual residue 
level.   
Thrombin is highly dynamic and adopts distinct states in the presence of ligands, 
which enable this enzyme to fulfill its array of protease activities.56,132-135   Previous NMR 
studies of thrombin revealed that there are key residues within the 30s and 70s loop regions 
of ABE I that cannot be monitored by NMR.56,132-135  Some of these thrombin residues 
become NMR-visible following introduction of ABE I ligands, whereas others do not. 
Intriguingly, surface loops and the ABE I region can remain flexible even when the active 
site of thrombin is inhibited.133-135  Because of the flexible nature of thrombin, development 
of the mature 30s and 70s loop regions can be challenging to probe. To overcome this issue, 
a novel NMR titration approach was needed.  For the current project, the PAR3 (44-56) 
peptides were labeled with 15N at the amide nitrogen of specific amino acid residues, and 
ProT and thrombin remained unlabeled.136 
Critical NMR information about how the PAR3 peptide (44-56) responds to the 




titration studies first revealed that the native PAR3 (44-56) sequence bound too tightly to 
be monitored by NMR. A P51G substitution was successful in decreasing the PAR3 
affinity. One-dimensional (1D) 1H line broadening NMR studies revealed that PAR3G (44-
56) could bind to immature pro-ABE I on ProT and also mature ABE I on thrombin. 1H-
15N- heteronuclear single -quantum coherence (HSQC) NMR titrations were then perfomed 
with selectively labeled PAR3G peptides.  Acidic PAR3G 15N-E48 and 15N-D54 both 
entered into higher affinity, intermediate exchange regimes as ProT was converted to 
thrombin. Strong binding events involving PAR3G D54 could be weakened with thrombin 
mutant R77aA, thus supporting the presence of a salt bridge.  By contrast, PAR3G [15N-] 
F47 and [15N-] L52 both bound more weakly to ProT/thrombin than the acidic PAR3G 
residues did.  Furthermore, [15N-] F47 and [15N-] L52 were able to document important 
changes to the hydrophobic exosite environment as pro-ABE I matures to ABE I. 
 
MATERIALS AND METHODS 
 
Materials  
Human plasma Prothrombin (ProT) and thrombin were purchased from Haematologic 
Technologies, Inc (Essex Junction, VT).  Recombinant thrombin mutant R77aA 
(chymotrypsin numbering) was a kind gift from E. Di Cera and L. Leslie Pelc (St. Louis 
University School of Medicine, St. Louis, MO).137 R77a is an extra thrombin amino acid 
residue located after E77, which is not found in chymotrypsin.  For the R77aA project, the 
basic R77a was replaced with a small, neutral A. The active sites of the thrombin species 
were protected from autolysis by blocking with PPACK (D-phenylalanyl-L-prolyl-L-




from Calbiochem (San Diego, CA). D2O (99.96%) was from Cambridge Isotope 
Laboratories (Andover, MA)                                                                                                   
 Synthetic Peptides 
A series of PAR3 -based peptides were custom synthesized by New England Peptide 
(Gardner, MA). PAR3 (44Q N T 15F E E F P L S 15D I E56), abbreviated as PAR3 (44-56), 
is the original PAR3 sequence, and amino acid residues F47 and D54 were labeled with 
15N at their amide nitrogens. PAR3 (44-56, P51G, 15F47, 15D54) (44Q N T 15F E E F G L S 
15D I E56), abbreviated as PAR3GFD (44-56), contains a Pro51 to Gly substitution (G) and 
furthermore, F47 and D54 were labeled with 15N.  PAR3 (44-56, P51G, 15E48, 15L52) (44Q 
N T F 15E E F G 15L S D I E56), abbreviated as PAR3GEL (44-56), also contains the P51G 
substitution (G) but now E48 and L52 are labeled with 15N. The purity of each synthesized 
peptide was verified by high-performance liquid chromatography and matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry. Initial stock solutions of peptide 
were solubilized in deionized water, and the concentration was determined by amino acid 
analysis (AAA Service Laboratory, Inc., Damascus, OR). Peptides were later diluted into 
25 mM H3PO4, 150 mM NaCl, and 0.2 mM EDTA (pH) 6.5 for NMR studies.   
The proton chemical shift values for all the PAR3 peptide amino acid residues were 
determined using a combination of two-dimensional (2D) TOCSY and 2D-transferred 
NOESY 65,109 experiments performed on a Varian Inova 700 MHz NMR spectrometer. 
Standard TOCSY and NOESY pulse sequences were employed. As is typical for trNOESY 
experiments, the ligand-protein complex contained a 10-fold excess of PAR3 (44-56) 
peptide fragment, and the chemical shifts report on the solution environment encountered 




assignments derived from the TOCSY and trNOESY experiments were later matched with 
their respective peaks found in 1H-15N HSQC NMR experiments.  Both 1H and 15N values 
could be followed in the HSQC titrations. 
Theoretical Basis for 1D Proton Line Broadening NMR and 1H-15N HSQC NMR  
1D proton line broadening studies were performed to monitor binding of the 
PAR3/PAR3G (44-56) peptide fragment to prothrombin versus thrombin.109-111 Protein-
peptide complexes were prepared with a 10-fold excess of peptide. Peptide protons that 
undergo interactions experience transient on/off events that cause an increase in the proton 
transverse relaxation rate and/or cause changes in the observed chemical shift position 
depending on the time scale of the interaction. The resultant alterations in peptide proton 
line width/shape reflect the weighted contributions of bound and free populations. This 
NMR line broadening approach can help map the peptide residue protons that come into 
direct contact with the protein surface.109,110  
1H-15N HSQC NMR titrations were used to assess whether specific 15N-labeled 
residues located within a peptide ligand exhibited fast, intermediate, or slow exchange 
on/off a protein surface.138  In these titrations, changes in chemical shift are monitored as 
a function of protein-ligand ratios. For weak binding, the interaction is under the fast 
exchange regime (kex >> |Δω|) where kex is the exchange rate of the interaction and Δω is 
the resonance frequency difference between the bound and free states. Only one signal per 
15N-labeled residue is observed reflecting the population-weighted average of bound and 
free states in terms of chemical shift, intensity, and line width. Furthermore, NMR chemical 
shifts can be used to quantitatively evaluate affinities for individual 15N labeled 




15N peak may disappear during the titration because of extensive line broadening and with 
an increase in the bound population will later reappear. Finally, for tight binding in which 
the interaction is described by the slow exchange regime (kex << |Δω|), two sets of 
resonances are observed: one corresponding to the free and the other to the bound state. 
Under this situation, the change in the intensity of the peaks will correspond to the relative 
population of each state during the course of the titration.   
Sample Preparation and Analysis for 1D Proton Line Broadening Experiments 
All NMR experiments were performed at pH 6.5 and at 25 °C. Under these conditions, 
the highly exchangeable [15N-] amide proton could still be readily observed by NMR at pH 
was not far from physiological (7.4). To prevent autolysis, the serine protease inhibitor 
PPACK was added to thrombin at a ratio of 4:1, and the mixture was incubated at 37 °C 
for 30 min. Previous NMR relaxation studies have confirmed that the ABE I region remains 
flexible in PPACK-inhibited IIa and can engage in long-range communication across the 
enzyme surface.135  Plasma versions of ProT and PPACK- thrombin were buffer exchanged 
into NMR buffer- [25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, (pH 6.5)] using a 
Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff (Sartorius, 
Göttingen, Germany). Protein concentrations were determined using extinction 
coefficients (E1%280 nm) of 18.3 for thrombin and 13.8 for ProT.  
Ligand-protein complexes with ratios of at least 10:1 were then prepared. The 
complexes included 1 mM PAR3 (44-56) with 74 M ProT, 1 mM PAR3 (44-56) with 77 
M PPACK-thrombin, 960 M PAR3G (44-56) with 76 M ProT, and 1 mM PAR3G (44-
56) with 76 M PPACK-thrombin. The peptide at a minimum concentration of 1 mM was 




were performed on a Varian Inova 700 MHz spectrometer with a triple resonance cold 
probe and pulsed-field Z-axis gradients run at 25 °C. The 1H NMR spectra were processed 
using Mnova NMR (Mestrelab Research software).   
2D 1H-13C HSQC Natural Abundance Experiments 
Before proceeding to 1H-15N HSQC NMR titrations, we performed 1H-13C HSQC 
natural abundance experiments on both PAR3 (44-56) and PAR3G (44-56) to assess 
whether the proline to glycine substitution would change the PAR3 peptide conformations. 
For this project, 1 mM PAR3 and 1 mM PAR3G were prepared in NMR buffer- ([25 mM 
H3PO4, 150 mM NaCl, and 0.2 mM EDTA, (pH 6.5)]. Parameters for the 2D 
1H-13C HSQC 
project included 128 transients with 64 complex points in the indirect dimension, sweep 
widths of 8064.5 and 24635.3 Hz for the direct and indirect dimensions, respectively, and 
3000 complex points acquired in the direct dimension. 2D 1H-13C HSQC data were 
processed using NMRPipe and nmrDraw and then further visualized using Sparky. The 
ability to superimpose the spectra of PAR3 (red) and PAR3G (black) confirmed that 
replacement of proline with flexible glycine did not change the overall peptide structure 
(Appendix 1) 
1D and 2D 1H-15N HSQC NMR Titration 
ProT and active site inhibited PPACK- thrombin were exchanged into NMR buffer 
using Vivaspin 2 ultrafiltration units with a 5000 Da molecular weight cutoff. A series of 
protein–ligand complexes were then prepared involving PAR fragments PAR3 (44-56), 
PAR3GFD (44-56), and PAR3GEL (44-56).  ProT and PPACK-thrombin exhibit limited 
solubility at the high concentrations typically used for NMR titrations. As a result, an 




concentration typically started in the range of 100-200 μM and was serially diluted while 
maintaining a constant concentration of 15N-labeled ligand. These conditions were 
achieved by removing a certain volume of the protein-ligand solution and replacing it with 
the same volume of the ligand solution. The titrations were thus initiated with a high 
protein: ligand ratio and ended with low protein: ligand ratios all while maintaining a 
constant peptide ligand concentration.  The NMR titrations were therefore monitoring the 
ability of ProT or thrombin to bind to the 15N-labeled PAR3 fragment.   
For the first PAR3 binding studies, the starting complexes included 50 M PAR3 (44-
56) in either 137 M ProT or 210 M PPACK-thrombin. The serial dilutions resulted in 
ProT: PAR3 ratios that spanned from 3:1 to 0.1:1. PPACK-thrombin: PAR3 ratios spanned 
from 4:1 to 0.1:1.  For the PAR3GFD binding studies, starting complexes included 37.5 M 
PAR3GFD (44-56) in 70 M ProT or in PPACK-thrombin. ProT: PAR3GFD ratios during 
the titrations then spanned from 2:1 to 0.3:1. PPACK-thrombin: PAR3GFD ratios spanned 
from 2:1 to 0.05:1.  
To evaluate the importance of electrostatic interactions between the 15N-labeled D54 
of PAR3GFD and R77a of wild-type thrombin, a series of 1D and 2D 
1H-15N HSQC 
titrations involving recombinant thrombin mutant R77aA and PAR3GFD were perfomed. 
The stock solution of R77aA thrombin was in 20 mM Tris (pH 7.4) and 400mM NaCl. 
After PPACK treatment, active site inhibited R77aA thrombin was buffer exchanged into 
25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, (pH 6.5) using a 3 mL Slide-A-Lyzer 
Dialysis cassette G2 (Thermo Scientific, Rockford, IL) with a 3500 Da molecular weight 
cutoff and then concentrated using a 5000 Da molecular Weight Cut Off Vivaspin 2 




PPACK-thrombin (R77aA). PPACK-thrombin (R77aA) to PAR3GFD ratios spanned from 
3:1 to 0.1:1.  
For the PAR3GEL binding studies, the starting complexes included 50 M PAR3GEL 
(44-56) with either 180 M ProT or 211 M PPACK-thrombin. The protein: ligand ratio 
of ProT to PAR3GEL and PPACK to thrombin to PAR3GEL complexes spanned from 4:1 
to 0.1:1.  
Parameters for the 1D 1H-15N HSQC titrations included 512 transients, sweep width of 
7022.5 Hz, and 1242 complex points in the direct dimension with PAR3 and 4096 with the 
PAR3G complexes. Parameters for the 2D 1H-15N HSQC titrations included 16 transients 
with 64 complex points in the indirect dimension, sweep widths of 7022.5 Hz and 1944.3 
Hz for the direct and indirect dimensions, respectively, and 1242 complex points acquired 
in the direct dimension. The 15N labeled free peptide was used as a control for each titration. 
1D 1H-15N HSQC data were stacked using Mnova NMR and 2D 1H-15N HSQC data were 
processed using NMRPipe and nmrDraw and then further visualized using Sparky. 
Quantitative estimates of binding interactions between individual 15N-labeled peptide 
ligand residues and specific proteins were determined using in-house scripts written using 
Python.140  Information provided to such scripts included the total enzyme ([𝑃0 ]) and total 
peptide ([𝐿0 ])  concentrations employed in the different steps of the HSQC titrations.  In 
addition, the NMR chemical shift difference (Δobs) between each set of free and bound 
conditions was provided. For the current NMR project, it is important to note that the 
peptide ligand concentration was kept constant and the protein was serially diluted.  As a 




concentration.  The equation for determining the binding affinity values (KD) was thus 
modified so that the denominator now contains [𝐿0 ] instead of the more typical [P0].
138,139     
𝛥𝑜𝑏𝑠 = 𝛥𝑚𝑎𝑥 ∗
(𝐾𝐷+[𝐿0 ]+[𝑃0 ])−√(𝐾𝐷+[𝐿0 ]+[𝑃0 ])2  −(4[𝑃0 ][𝐿0 ])
2[𝐿0 ]
                   (1) 
NMR titrations were performed at least in triplicate to determine KD values involving 
plasma- derived ProT and thrombin.  Duplicate titrations were performed for thrombin 
R77aA.  An error analysis of the KD values was performed using a Monte-Carlo approach 
in which a 10% error was imposed on the serially diluted thrombin concentration. 140 
 
RESULTS 
1D Proton Line Broadening NMR Studies with PAR3 (44-56)  
One dimensional 1H line broadening NMR experiments were performed on PAR3 
(44-56) in the presence of ProT versus PPACK- thrombin (Figure 30 A-C). The active site 
inhibitor PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) was used to 
protect thrombin from autolysis during the NMR experiments. Proton (1H) peak 
broadening could be detected for aliphatic, amide, and aromatic protons of PAR3 in 
complex with ProT. Such results indicate that a binding surface for PAR3 (44-56) is already 
available within the immature pro-ABE I on ProT.  Substantial peak line broadening was 
also observed when the peptide was introduced into a solution of PPACK-thrombin 
containing mature exosite ABE I.  Such broadening is impressive considering the lower 
molecular weight of thrombin (37 kDa) versus that of ProT (72 kDa).111 The overall, 
extensive thrombin-induced peak broadening provides further justification that mature 




observed across the different Figure 30 panels make it difficult to quantitatively evaluate 














15N-HSQC Titration Studies with PAR3 (44-56) Labeled at D54 and F47 
An HSQC titration project was designed to systematically characterize binding of 
PAR3-based peptides that are selectively labeled at amide nitrogen locations. The X-ray 
crystal structure of the thrombin - PAR3 (44-56) complex was first consulted to select sets 
of acidic and hydrophobic amino acid residues of PAR3 that display interactions with the 
30s and 70s loop regions on thrombin (Figure 28).50  2D total correlation spectroscopy 
(TOCSY) spectra of the bound PAR3 peptide then provided a valuable guide for choosing 
Figure 30: Proton line broadening spectra for PAR3 and PAR3G peptides in the presence of 
prothrombin and PPACK-thrombin. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 
mM EDTA and 10 % D2O (pH 6.5). A) 1D 1H-NMR spectrum of 1 mM PAR3 (44- 56) peptide in 
solution B) 1D 1H-NMR spectrum of 1 mM PAR3 (44-56) in the presence of 74 μM ProT C) 1D 
1H NMR spectrum of 1 mM PAR3 (44-56) in the presence of 77 μM PPACK-IIa D) 1D NMR 
spectrum of 1 mM PAR3G (44- 56) in solution E) 1D 1H NMR spectrum of 960 μM PAR3G (44-
56) in the presence of 76 μM ProT. F) 1D NMR spectrum of 1 mM PAR3G (44-56) in the presence 
of 76 μM PPACK-IIa. Line broadening was observed for residues of PAR3 (44-56) and PAR3G 
(44-56) when either peptide was bound to prothrombin and PPACK- IIa. The amide protons that 





amino acid residues with amide chemical shift positions that would be less likely to overlap 
in the proton dimension during the course of the PAR3-protein 1H-15N HSQC titrations.  
The first amino acid residues selected included PAR3 F47 and D54. According to the 
X-ray crystal structure, acidic PAR3 D54 makes a salt bridge contact with thrombin R77a 
of the 70s ABE I loop whereas PAR3 F47 exhibits π-π stacking interactions with thrombin 
F34 in the 30s ABE I loop region (Figure 28).50  15N-HSQC NMR titrations were thus 
performed with PAR3 (44-56) labeled with 15N at D54 and F47. These two PAR3 residues 
both exhibited proton line broadening in the presence of ProT and PPACK-thrombin 
confirming contact with the target protein in solution (Figure 30A-C).    
The HSQC titrations started out with a 3:1 ProT: PAR3 ratio (containing the 
[15N]D54 and [15N-]F47 residues). Extensive peak broadening was observed for both [15N-
] D54 and [15N-]F47 until the ProT:PAR3 ratios were serially diluted to 0.3:1 (D54) or 
0.6:1 (F47) and lower. With PPACK-thrombin, peaks for both PAR3 residues could not be 
detected until ratios of 0.3:1 were reached (Appendix 2 and 3). These NMR results 
suggest that PAR3 D54 and F47 can already interact with pro-ABE I on ProT, and tightens 
in the presence of PPACK-thrombin with a mature ABE I.   
Proton Line Broadening NMR and 15N-HSQC NMR Titration Studies with PAR3GFD 
(44-56) Labeled at D54 and F47 
The extensive line broadening observed for PAR3 (44-56) bound to PPACK-IIa was 
a major hindrance for 15N-NMR titration studies, and binding affinities could not be 
determined.  To weaken this interaction, a modified sequence was designed in which the 
P51 was replaced with a flexible glycine (P51G). The resultant PAR3GFD (44-56) showed 




abundance 13C HSQC spectra were recorded for both PAR3 peptides.  As seen Appendix 
2, the two spectra show good overlap suggesting that the Pro to Gly substitution has not 
caused substantial changes to the conformation or the chemical environments of the two 
peptides.   
1H-15N HSQC titrations were then performed with PAR3GFD containing 
15N-labeled 
D54 and F47.  The ProT:PAR3GFD ratios spanned from 2:1 to 0.3:1 and PPACK thrombin: 
PAR3GFD ratios spanned from 2:1 to 0.05:1. Results from 1D displays of the 
15N-HSQC 
studies revealed that the PAR3GFD D54 peak became more broadened than the F47 peak 
in the presence of ProT and PPACK-thrombin (Appendix 4). Further information about 
interactions occurring with these two proteins was obtained by examining the 2D HSQC 
titrations (Figures 31A and 31B). In the presence of ProT, the PAR3GFD residue D54 
exhibited changes in chemical shift that resemble a fast exchange scenario corresponding 
to an interaction with weakened affinity.  This interaction creates a new protein 
environment for the ligand. By contrast, PAR3GFD residue F47 residue exhibited little 
change in chemical shift during the ProT titration suggesting this residue did not experience 
a substantial change in its chemical environment relative to that of the free peptide (Figure 
31A). The project then proceeded to titrations with PPACK-thrombin where additional new 
effects were observed.  The 2D HSQC crosspeak for D54 underwent extensive line 
broadening and could only be observed for thrombin: PAR3GFD ratios of 0.16:1 to 0.05:1 
(Figure 31B). Such a peak broadening reflects improved interactions with the mature ABE 
I site and is consistent with intermediate exchange conditions. Interestingly, the F47 




0.05:1 titration series. F47 was now experiencing a chemical environment different from 







The chemical shift changes for the D54 and F47 titrations proceed in the same 
directions across the NMR panels when probing ProT versus PPACK-IIa (upfield for F47 
and downfield for D54). These similarities are consistent with the PAR3 and PAR3G 
peptides interacting within the same binding region of ProT versus PPACK-IIa. 
Nonspecific binding to a separate area on ProT is not evident.  In further support of this 
proposal, Andersen et al. confirmed that hirudin (54-65) can bind specifically to the (pro)-
exosites of prothrombin and thrombin.126  Moreover, HDX-MS studies demonstrated that 
hirudin and PAR3 (44-56) both bind to thrombin ABE I region 65-84.60 
NMR HSQC titrations can be used to quantitatively characterize binding interactions 
for individual 15N-labeled amino acid residues. These calculations work the best when there 
are distinct changes in chemical shift position when 15N-labeled peptide amino acid 
 
Figure 31: 2D 1H-15N HSQC NMR titrations of PAR3GFD (44-56) in the presence of ProT and 
PPACK- IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O 
(pH 6.5). A) For the PAR3GFD binding studies with ProT, starting complexes included 37.5 M 
PAR3GFD (44-56, [15N]-F47, [15N-]D54) in 70 M ProT. The serial dilutions resulted in 
ProT:PAR3GFD ratios that spanned from 2:1 to 0.3:1. B) For PPACK -IIa, starting complexes included 
37.5 M PAR3GFD (44-56, [15N-]F47, [15N-]D54) in 70 M PPACK-IIa. The serial dilutions resulted 
in PPACK-IIa:PAR3GFD ratios that spanned from 2:1 to 0.05:1. Representative data sets are shown.  





residues interact with a target protein. Furthermore, the binding curves should approach 
saturation.138,139 With the current project, the peptide concentration remained constant, and 
the protein solutions were serially diluted. For these protein- peptide ligand systems, 
affinity estimates could be made for some of the 15N-labeled PAR3G (44-56) amino acid 
residues. On the basis of the titration data that were collected, D54 had a binding affinity 
(KD) of 65 ± 12 µM in the presence of ProT and a maximal chemical shift difference 
(Δωmax) of 0.39± 0.03 ppm. (Table 3, and Figure 32B). The interaction became stronger 
with thrombin, however, the binding of D54 was too tight and the peak broadening was too 
severe to determine a KD value from the titration curve. The labeled PAR3 F47 residue had 
an estimated KD value of 64 ± 8 µM and a Δωmax of 0.23± 0.01 ppm for ProT and a KD 
value of 40 ± 10 µM and a Δωmax of 1.98 ± 0.19 ppm with thrombin (Table 3, and Figures 
32A and C). Curiously, F47 experienced a marginal increase in affinity upon exosite 
maturation even though this residue clearly encountered a new environment reflected by 
its now larger chemical shift spread (Δωmax) (Table 3, and Figure 32C) 














































Table 3: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR3GFD 
and PAR3GEL Bound to Human Prothrombin and Thrombin (wild type and mutant)a  
 
aFor these NMR titrations, the peptide ligand concentrations were kept constant and the protein concentrations were serially 
diluted.  Estimated KD were calculated using in house scripts written in Python.  Experimental data employed in the calculations 
include the individual protein and peptide concentrations and also the 15N NMR chemical shift differences between each set of 
free and bound conditions.  The plasma-derived ProT and IIa titration series were carried out at least in triplicate.  The studies 
with recombinant R77aA-IIa were done in duplicate. Error analysis was carried out using a Monte-Carlo approach assuming a 




































15N-HSQC NMR Titration Studies with PAR3G (44-56) Labeled at D54 and F47 
Interacting with the Thrombin Mutant R77aA  
The HSQC titrations described above revealed a significant increase in affinity for 
PAR3 residue D54 as ProT is converted to thrombin. Acidic PAR3 D54 has been reported 
to make salt bridge contact with basic thrombin residue R77a (Figure 28).50  Interactions 
between these two residues likely become more effective once the mature ABE I is formed. 
To probe whether electrostatic interactions are occurring between R77a and D54, 1H-15N 
HSQC titrations were performed with a thrombin R77aA - PAR3GFD complex (Figure 33). 
Figure 32: Determination of the binding Affinity (KD) for 15N-labeled F47 and D54 of PAR3GFD 
interacting with prothrombin and PPACK-IIa. For this NMR titration series, the peptide ligand 
concentration was kept constant and the ProT and PPACK-IIa concentrations were serially diluted.  
As a result, the NMR titrations were measuring the binding of protein to a defined peptide 
concentration. Interactions between A) ProT and PAR3G [15N-]F47 led to a KD of 64 ± 8 µM, B) 
ProT and PAR3G [15N-]D54 led to a KD of 65 ± 12 µM, and C) PPACK-IIa and PAR3G [15N-]F47 
led to a KD of 40 ± 10 µM.  NMR titrations were perfomed in triplicate.  The reported KD values 
were determined using in-house scripts written using Python. The term |Δδobs| 15N ppm = δ15Nbound – 
δ15N free reflects the absolute difference in chemical shift between the bound and free states of the 
particular 15N-residue. Error analysis was performed using a Monte-Carlo approach assuming a 10% 





Unlike the wild-type PPACK-thrombin titrations, D54 and F47 chemical shifts could be 
followed for the full titration series for PPACK-thrombin R77aA: PAR3GFD ratios of 3:1 
to 0.13:1. The D54 crosspeak exhibited a broad range of chemical shifts and even 
overlapped with the F47 crosspeak for a portion of the titration (Figures 33A and 33B). 
Note in Figure 33A that at the start of the titration (3:1 protein:peptide ratio) the amide 
proton for PAR3G F47 was at 8.3 ppm and for PAR3G D54 at 8.2 ppm.  By a ratio of 0.7:1, 
the two peaks overlapped into a single peak.  As the PPACK-R77aA was further diluted, 
the F47 and D54 peaks continued to change resonance positions and eventually matched 
those of the free PAR3GFD peptide. A similar set of trends can be observed in the 2D HSQC 
crosspeaks shown in Figure 33B. Overall, the 2D crosspeak patterns for both F47 and D54 
were consistent with fast exchange conditions. For PAR3G D54, the estimated KD was 168 
± 88 µM and the Δωmax = 1.83 ± 0.62 ppm, whereas for PAR3G F47 the values were a KD 
of 173 ± 85 µM and the Δωmax = 1.79 ± 1.05 ppm (Table 3, and Appendix 6A and, B). The 
removal of the salt bridge between PAR3 D54 and thrombin R77a clearly weakened the 
interaction of D54 with the ABE I surface, and a KD value could now be estimated. In 
addition, an 3-fold loss of affinity was observed for PAR3G F47 in the presence of the 
R77aA thrombin mutant. Even with the weakened affinity, thrombin R77aA still incurred 



























15N-HSQC NMR Titration Studies with PAR3G (44-56) Labeled at L52 and E48 
Two additional PAR3 residues were chosen to probe the environments of the 30s and 
70s loop regions of (pro)-ABE I. E48 of PAR3 (44-56) makes a salt bridge with R75 of 
thrombin, and L52 of PAR3 (44-56) is positioned within a hydrophobic pocket containing 
thrombin residues F34, L65, and I82 (Figure 28).50   As observed with F47 and D54, the 
two new PAR3 residues E48 and L52 also exhibited 1D proton line broadening when 
Figure 33: 1D and 2D 1H-15N HSQC NMR titrations of PAR3GFD (44-56) in the presence of 
PPACK- R77aA. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 
% D2O (pH 6.5). A) For the 1D HSQC NMR titrations, the starting complexes included 50 M 
PAR3GFD (44-56, 15N-F47, 15N-D54) in 150 M PPACK- R77aA. The serial dilutions resulted in 
PPACK- R77aA:PAR3GFD ratios that spanned from 3:1 to 0.1:1. Note that at the start of the titration 
(3:1 protein to peptide) the amide proton for PAR3G F47 was at 8.3 ppm and for PAR3G D54 at 8.2 
ppm.  By a ratio of 0.7:1, the two peaks overlapped into a single peak.  As the PPACK-R77aA 
thrombin was further diluted, the F47 and D54 peaks continued to change resonance positions and 
eventually matched those of the free PAR3GFD peptide.  Representative data sets are shown. B) For 
the 2D 1H-15N HSQC titrations, starting complexes included 50 M PAR3GFD (44-56, [15N-]F47, 
[15N-]D54) in 150 M PPACK- R77aA. The serial dilutions resulted in PPACK-thrombin: PAR3GFD 
ratios that spanned from 3:1 to 0.1:1. Representative data sets are shown.  Colors for the 2D 1H-15N 





complexed with ProT and PPACK-IIa (Figure 30). Thus, HSQC NMR titrations could be 
performed with PAR3G (44-56) labeled at [15N-]E48 and [15N-]L52.  
The titration ratios for ProT-PAR3GEL and (PPACK-thrombin)-PAR3GEL spanned 
from 4:1 to 0.1:1. For the ProT bound complex, 1D and 2D displays of HSQC titration 
peaks could be followed for all the titrations points (Appendix 5A and Figure 34). Unlike 
those of PAR3GFD, the binding affinities for L52 and E48 were weaker resulting in KD 
values of 124 ± 27 and > 200 µM, respectively (Table 3, Figure Appendix 7A and 
Appendix 8B). Moreover, both E48 and L52 exhibited fewer changes in chemical shift 
position. These results suggested that E48 and L52 did not encounter much of a change in 







Furthermore, we propose that ProT R75 is less available for interacting with E48 
of PAR3 than the distinct interactions already observed between ProT R77a and D54 of 
PAR3. When the peptide was titrated with PPACK- thrombin (Appendix 6B and Figure 
34B), L52 exhibited a greater change in chemical shift position. By contrast, E48 
Figure 34: 2D 1H-15N HSQC NMR titrations of PAR3GEL (44-56) in the presence of ProT and 
PPACK- IIa. All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % 
D2O (pH 6.5).A) For the PAR3GEL binding studies with ProT, starting complexes included 50 M 
PAR3GEL (44-56, 15N-E48, 15N-L52) in 180 M ProT. The serial dilutions resulted in ProT to 
PAR3G ratios that spanned from 4:1 to 0.1:1. B) For the PPACK - IIa, starting complexes included 
50 M PAR3GEL (44-56, 15N-E48, 15N-L52) in 211 M PPACK- IIa. The serial dilutions resulted 
in PPACK- IIa to PAR3GEL ratios that spanned from 4:1 to 0.1:1. Representative data sets are 
shown.  Colors for the 2D 1H-15N HSQC crosspeaks span from blue (highest protein-peptide ratio) 





resembled intermediate exchange on/off the thrombin surface.  Extensive peak broadening 
could already be observed at 1.2:1 protein: ligand ratios. In the presence of PPACK- 
thrombin, L52 showed a 3-fold improvement in KD (47 ± 6 µM) and E48 underwent 
extensive peak broadening preventing a KD value from being calculated.  For L52, a Δωmax 
of 0.37 ± 0.04 ppm was obtained for ProT and increased to 1.84 ± 0.08 ppm upon 
conversion to thrombin (Table 3, and Figures Appendix 7A, C). 
DISCUSSION 
With thrombosis becoming a global disease burden, the urge to develop better 
anticoagulants has increased.87  Novel oral anticoagulants 141,142 that target the active sites 
of FXa and thrombin 143 have shown much medical promise but reversing their therapeutic 
activities during heavy bleeding scenarios can be challenging.144,145  Drug candidates 
123,124,146 that target thrombin ABE I are an alternative strategy. Thrombin is, however, 
proteolytically derived from the zymogen prothrombin (Figure 27).  Unexpectedly, some 
ABE I ligands can already bind to the immature pro-ABE I site on this zymogen. 
101,125,126,128,147 Future ABE I directed therapeutics might therefore be designed to target or 
avoid specific regions of pro-ABE I on ProT versus ABE I on thrombin.   
With our NMR titration approaches, we characterized, for the first time, the binding of 
ABE I directed PAR3 peptides to ProT versus PPACK-thrombin. Previous NMR relaxation 
studies had already revealed that communication from ABE I toward the active site region 
is still preserved with PPACK-thrombin.133  Our 1D 1H line broadening NMR results 
demonstrated that PAR3 (44-56) and its weaker binding version PAR3G (44-56) could 
interact with both ProT and PPACK-thrombin (Figure 30).50  NMR 1H-15N-HSQC titration 




ability to bind ProT versus PPACK-thrombin (Figure 31-34, and Figure Appendix 1-8). 
Such an approach has the distinct advantage of monitoring exosite maturation at the 
individual amino acid residue level.  Isothermal titration calorimetry, fluorescence, and 
surface plasmon resonance all provide a global KD fit using all peptide amino acid residues.  
NMR, by contrast, preserves the ability to measure individual binding interactions in 
solution and thus document their contributions.  Moreover, NMR works best with weaker 
affinity systems. 
For the current NMR project, PAR3 peptides were prepared with [15N-] amide labeling 
of F47, E48, L52, and D54. HSQC titrations were performed at the typical NMR pH of 6.5. 
The acidic and hydrophobic residues [15N-] D54 and [15N-]F47 on PAR3 (44-56) were 
examined first.  This native PAR3 sequence bound too tightly to thrombin hindering ability 
to assess KD values by NMR titration methods. Prior fluorescence titrations revealed a KD 
of 2 µM for a related PAR3 sequence thus confirming our observation of intermediate/slow 
exchange conditions in the NMR titrations.148  Greater success was achieved with 
PAR3GFD (44-56) in which P51 was replaced with G51.  With ProT, PAR3G D54 and F47 
both had individual KD values in the range of 65 µM. The immature pro-ABE I can thus 
accommodate both residues to a similar extent. Upon maturation to ABE I, PAR3G D54 
bound too tightly to PPACK-thrombin for binding affinity calculation. By contrast, the F47 
binding affinity increased only modestly as ProT was converted to thrombin.  Interestingly, 
the F47 also documented a substantial change in the chemical environment (Δωmax = 1.8 
ppm) within the 30s loop region following activation to thrombin. Structural 
rearrangements are proposed to occur in the vicinity of ProT/thrombin residue F34 but do 




The PAR3G D54 residue was hypothesized to be influenced by its electrostatic 
interaction with thrombin R77a (Figure 28).50  This acidic PAR3 residue may have 
properties similar to those of hirudin.149  The hirudin sequence (56FEEI59) has already been 
proposed to electrostatically steer toward the ABE I surface.149,150  Ionic tethering between 
acidic hirudin residues and specific basic residues on ABE I might then be promoted 
followed by stabilizing hydrophobic interactions.149,150  These hypotheses could now be 
tested with the PAR3G sequence and thrombin R77aA.  As predicted, the affinity for D54 
weakened 3-fold upon loss of its salt bridge partner.  In response, the F47 also displayed a 
much weaker affinity value.   
PAR3G residues E48 and L52 provided the opportunity to probe two additional regions 
of ProT versus PPACK-thrombin.  E48 makes a salt bridge with thrombin R75, a 
neighboring region of the 70s loop.  PAR3G L52 interacts with a cluster of hydrophobic 
residues including thrombin F34, L65, and I82 (Figure 28).50  Curiously, both E48 and L52 
exhibited only minor changes in chemical shift upon binding to ProT.  Furthermore, the 
estimated individual KD values for L52 and E48 bound to ProT were 2-fold weaker than 
those for D54 and F47.  The pro-ABE I surface on ProT may not accommodate these two 
residues as well as it does PAR3 D54 and F47.  Similar to PAR3G D54, there was extensive 
line broadening for E48 upon conversion to thrombin and KD values could not be 
determined.  By contrast, L52 exhibited a broad series of chemical shift changes during the 
thrombin titration (Δωmax = 1.8 ppm).  Interestingly, the estimated KD for binding of L52 
(KD = 47 ± 6 µM) to PPACK-thrombin was similar to the value determined for F47 (KD = 
40 ± 10 µM).  Both L52 and F47 interact at the more hydrophobic surface area of ABE I 





Overall, our solution NMR studies have elucidated changes in the exosite 
environment that occur as zymogen ProT is converted to active thrombin. 1D proton line 
broadening NMR and 1H-15N-HSQC studies demonstrated that PAR3G E48 and D54 could 
already interact with ProT and the affinity increased upon maturation to thrombin. In the 
NMR studies, the 3-fold tighter binding affinity for D54 versus that of E48 suggests that 
the 70s loop region surrounding thrombin R77a may be better oriented to bind PAR3G 
D54 than the interaction between thrombin R75 and PAR3G E48 (Figure 28).  Moreover, 
a close review of the crystal structure overlays in Figure 3 suggests that the 70s loop region 
of ProT may assume an orientation that is preconfigured to that of PAR3-thrombin and 
PPACK-thrombin.  As the ionic PAR3G D54 – ProT/IIa R77a and PAR3G E48- ProT/IIa 
R75 interactions are stabilized, PAR3G F47 and L52 are proposed to take further advantage 
of interacting with thrombin F34 (within the 30-40s loop) and the thrombin hydrophobic 
cluster F34, L65, and I82 (Figure 28). Aromatic PAR3G F47 and aliphatic PAR3G L52 
both reported on significant changes in the chemical environment upon conversion of ProT 
to thrombin. The region surrounding the ProT/IIa 30s loop appears to be more affected than 
the hydrophobic pocket containing F34, L65, and I82.   
Curiously, no striking differences are observed between the crystal structures of 
immature pro-ABE I in ProT versus the mature ABE I regions of thrombin-ligand 
complexes (Figure 29).  Moreover, there are no X-ray crystal structures for a ligand bound 
to the pro-ABE I region of ProT.  We can speculate that there are transient structural states 
within this coagulation protein system that are differentially explored by ProT and 




Interestingly, ProT already possesses a binding competent state.  Additional research has 
implicated transient, or lowly populated, structures as playing an essential role in molecular 
interactions.151-153  Thus, we believe that the mature thrombin likely visits a binding 
competent state more often than ProT does, thereby promoting the higher affinity of PAR3 
for thrombin.  
In conclusion, our NMR titration studies have clearly revealed that individual 
PAR3 amino acid residues are documenting structural rearrangements that occur upon 
ABE I maturation. Moreover, these amino acid residues make individual contributions to 
the overall binding affinity. The knowledge gained from this NMR project may be used to 
help decipher the characteristic features of pro-ABE I versus ABE I that become accessible 
to physiological ligands or future drug candidates. 
 
NOTE: 
1.) 2D 1H-15N HSQC titration for PAR3GFD and thrombin without PPACK incubation was 
performed as a control experiment to verify whether chemical shift pattern of 15N-labeled 
F47 and D54 are in the same direction as the one with PPACK-incubation (Appendix 8).  
2.) This chapter is reproduced in part from the published manuscript:  
Ramya Billur, David Ban, T. Michael Sabo, Muriel C. Maurer. (2017). “Deciphering the 
Conformational Changes Associated with the Maturation of Thrombin Anion Binding 







BINDING INTERACTIONS OF PAR1 AND PAR3 FOR THROMBIN AND 
DISSECTING ALLOSTERIC LINKAGE BETWEEN THE EXOSITES  
 
INTRODUCTION 
Thrombin is a serine protease whose functions are controlled by surface loops and 
two anion binding exosites.48  These exosites ABE I and ABE II are located on opposite 
sides of the active site region (Figure 6 from chapter 1).37  Thrombin is originally 
expressed as the zymogen prothrombin (ProT) that contains immature exosites pro-ABE I 
and pro-ABE II (Figure 5 from chapter 1).38  These immature exosites convert into mature 
ligand binding sites upon activation of ProT to thrombin.48,57,89 
Unexpectedly, there are reports that ABE I directed ligands can already bind to 
immature pro-ABE I on ProT.125,126,128  In the previous chapter, we successfully 
demonstrated how NMR titrations could be used to decipher conformational changes that 
occur as pro- ABE I on ProT is converted into thrombin. In that project, a peptide based on 
the protease activated receptor PAR3 (46-54) was successfully shown to bind to ProT and 
affinity increased upon thrombin maturation.154  Moreover, the valuable roles that 
individual 15N-labeled PAR3 residues play in the binding process were determined. Both 
electrostatic (E48, D54) and hydrophobic residues (F47, L52) of PAR3 (46-54) made 




PAR3 is just one member of the protease activated receptor family. PARs are 
membrane bound proteins containing seven transmembrane domains. Among this family, 
thrombin exhibits the greatest substrate specificity towards PAR1 reflected by its highest 
kcat/Km.155  PAR1 is well known for its roles in platelet activation, aggregation, and for 
helping to trigger inflammatory processes.81,102,156,157  PAR1 has gained attention for its 
role in controlling the metastasis of cancer cells.158,159  
PAR1 needs to be activated for this receptor to initiate its biosignaling functions. 
Thrombin cleaves PAR1 at the R41-S42 peptide bond, and a portion of the new N-terminus 
then serves as a tethered ligand to help activate PAR1. The required cleavage of PAR1 at 
the thrombin active site is helped by having a portion of PAR1 also bind to thrombin ABE 
I. Interestingly, PAR3 and PAR1 have both been shown to bind at ABE I and assist in 
cleavage of PAR4 which lacks an ABE I binding segment. Following their activations, 
PAR1 and PAR4 can illicit transmembrane signaling events like coupling to heterotrimeric 
G-proteins, regulating kinase signaling cascades, and promoting receptor phosphorylation 
and internalization.156,160  
Gandhi and coworkers reported the X-ray crystal structure of PAR1 (33-62, 
33ATNATLDPRSFLLRNPNDKYEPFWEDEEKN62) bound to catalytically inactive 
thrombin S195A.49,85  The 38LDPRSFLLRNP48 segment spans the active site with thrombin 
cleavage occurring at the R41-S42 peptide bond. The segment 50DKYEPF55 is 
hypothesized to be important for binding to ABE I.149  Similar to other ABE I directed 
ligands such as hirudin51,161 and PAR3, this PAR1 sequence has both electrostatic and 




structure revealed that key thrombin sites located < 4 Å away from PAR1 include F34, 











PAR1 50DKYEP54, similar to 56FEEI59 of hirudin,161 is proposed to be responsible 
for docking PAR1 on to thrombin ABE I.  The next step is thought to be locking of 
38LDPR41 on to the thrombin active site for cleavage. Molecular modeling studies have 
suggested that the C-terminal 58DEEKN62 binds to ABE I, but this flexible PAR1 segment 
is not observed in the Gandhi X-ray crystal structure.49,85  Similar to our previous work 
with PAR3 peptides, solution NMR could provide a successful strategy to further map the 
binding of PAR1 to ABE I.154  Moreover, exosite maturation from ProT to thrombin could 
be explored.  
Figure 35: Crystal structure of thrombin in complex with human PAR1 fragment (49-57) PDB 
code 3LU9. The thrombin surface is rendered in gray. ABE-I residues that are located < 4 Å 
from PAR1 (49-57) are displayed as green ribbons or green sticks and PAR1 (49-57) in red 
sticks. The PAR1 residues later chosen for 15N-HSQC titration studies include residues D50, 





Events at thrombin ABE I can also be influenced by occupancy at ABE II. Similar 
to PAR1 and PAR3, glycoprotein GpIbα is also found on the surface of platelets. GpIbα 
recruits thrombin to the platelet environment by binding an anionic cluster (269-286) to 
thrombin ABE II (R93, R101, R126, K235, K236, and K240).79  GpIbα binding then affects 
a variety of thrombin functions. The GpIbα-thrombin complex enhances PAR1 
hydrolysis,80  hinders release of FpA,162  and decreases affinity for FVIII.163  Previous 
HDX-MS studies demonstrated that GpIbα binding at thrombin ABE II can influence the 
solvent accessibility of thrombin ABE I regions.60,78  There have been reports that 
Prothrombin F2 and Fibrinogen γ' can each bind to ABE II and also elicit both local and 
long range allosteric effects.164  Keeping these observations in mind, we wanted to further 
probe how GpIbα is involved in allosteric communication with ABE I bound ligands.  
X-ray crystal structures are available for prothrombin,120 active site inhibited 
thrombin,37 PAR1 bound thrombin,49 PAR3 bound thrombin,50 and GpIbα bound 
thrombin.52  An overlay of ABE-I regions for these proteins reveals no striking structural 
differences across the series (Figure 36). The backbone root mean square deviation for 
those five ABE-I regions range from 0.47 to 0.76 Å.131  Our current solution NMR titration 
methods have the ability to reveal conformational changes that occur upon activation of 
prothrombin to thrombin and to monitor how individual peptide ligand residues respond to 
the new environments.  Conformational changes that are transient in nature and may have 


















Important information on how individual PAR1 amino acids interact with ProT and 
mature IIa were obtained in this second NMR titration project. With our 1D 1H line 
broadening NMR experiments, we successfully monitored the native PAR1P sequence (49-
62) binding to immature zymogen Prothrombin (ProT) versus the mature protease thrombin 
(IIa). Proton line broadening for PAR1P (49-62) increased when bound to PPACK-IIa. 2D 
trNOESY suggested an extended conformation for PAR1 (49-62) with the Xaa-Pro 
adopting a trans conformation. Studies then proceeded to 1H-15N HSQC titrations using 
selectively labeled PAR1 peptides. 15N- labeled F55 of PAR1P interacted already with 
ProT indicating the existence of hydrophobic interactions with the immature exosite. 
However, NMR titrations with 15N- labeled PAR1P with PPACK-IIa could not be followed 
Figure 36: Structural alignment of the ABE I regions of prothrombin (PDB entry 4HZH), thrombin-
PAR1 (PDB entry 3LU9), and PPACK-thrombin (PDB entry 1PPB), thrombin- GpIb (PDB entry 1PBV 
and 1OOK).  Regions encompassing exosite I (residues F34-M84, thrombin straight numbering) were 
selected, and then a backbone alignment was performed using MolMol. The backbone ABE 1 root-mean-
square deviation values for the different protein -protein comparisons were then determined: 0.79 Å for 
ProT and thrombin-PAR1, 0.47Å for PPACK-thrombin and thrombin-PAR1, 0.63 Å for ProT and 
PPACK-thrombin, 0.76Å and 0.62Å for ProT and two crystal structures of GpIb, 0.48Å and 0.50Å for 





due to severe exchange broadening. Hence, a weaker binding version PAR1 (P54G) was 
employed for all 15N- labeled titrations. Upon ABE I maturation, the affinities increased 
for 15N- labeled K51, F55, and D58 of PAR1G (49-62) owing to the formation of more 
optimal contacts. For the first time, thrombin binding interactions could be monitored for 
PAR1G D58 and E60 which were missed in X-ray structures. By having GpIb bind at 
ABE II, long-range communication between exosites could be explored and effects on 
binding affinities determined. Both PAR1 (49-62) and PAR3 (44-56) responded to the 
presence of the ABE II ligand GpIb (269-286). New evidence is available that interactions 
between PARs and thrombin are ligand dependent.  
 
MATERIALS AND METHODS 
Materials  
Human plasma Prothrombin (ProT) and thrombin were purchased from 
Haematologic Technologies, Inc (Essex Junction, VT). The active sites of the thrombin 
species were protected from autolysis by blocking with PPACK (D-phenylalanyl-L-prolyl-
L-arginine chloromethyl ketone). This serine protease active site inhibitor was purchased 
from Calbiochem (San Diego, CA). D2O (99.96%) was from Cambridge Isotope 
Laboratories (Andover, MA).                                                                                                  
 Synthetic Peptides 
A series of PAR1 -based peptides was custom synthesized by New England Peptide 
(Gardner, MA). PAR1 (49N 15D K Y E P 15F W E D E E K N62), abbreviated as PAR1P 
(49-62), is the original PAR1 sequence, and amino acid residues D50 and F55 were labeled 
with 15N at their amide nitrogens. PAR1 (49N 15D K Y E G 15F W E D E E K N62) 




the D50 and F55 were labeled with 15N.  PAR1 (49-62, P54G, 15E53, 15D58) (49N D K Y 
15E G F W E 15D E E K N62), abbreviated  as PAR1GED (49-62), also contains the P54G 
substitution (G) but now E53 and D58 are labeled with 15N. PAR1 (49-62, P54G, 15K51, 
15E60) (49N D 15K Y E G F W E D E 15E K N62), abbreviated  as PAR1GKE (49-62), also 
contains the P54G substitution (G) , where K51 and E60 are labeled with 15N. PAR3 (44-
56), P51G, 15E48, 15L52) ( 44Q N T F 15E E F G 15L S D I E56), abbreviated as PAR3GED 
(44-56), contains the P51G substitution (G) , where E48 and L52  are labeled with 15N. 
GpIbα (269- 286) (269D E G D T D L YP P D YP P YP P P E E D T E G
289) with the three 
tyrosines phosphorylated was synthesized by Bachem Bioscience Inc. The purity of each 
synthesized peptide was verified by high-performance liquid chromatography and matrix-
assisted laser desorption ionization time-of-flight mass spectrometry. Initial stock solutions 
of peptide were solubilized in deionized water, and the concentrations were determined by 
amino acid analysis (AAA Service Laboratory, Inc., Damascus, OR). Peptides were later 
diluted into 25 mM H3PO4, 150 mM NaCl, and 0.2 mM EDTA (pH 6.5) for NMR studies.   
The 1H chemical shift assignments for all PAR1 peptide residues were derived from 
2D TOCSY and 2D trNOESY experiments. Standard pulse sequences were employed. 
Since the aromatic residues (F55 and W56) were challenging to assign for PAR1 (49-62), 
2D 1H-13C HSQC natural abundance experiments were also employed. For this project, 1 
mM PAR1P and 1 mM PAR1G were prepared in NMR buffer- [25 mM H3PO4, 150 mM 
NaCl, and 0.2 mM EDTA, (pH 5.4-6.5)]. Parameters for the 2D 1H-13C HSQC project 
included 128 transients with 64 complex points in the indirect dimension, sweep widths of 
8064.5 and 24635.3 Hz for the direct and indirect dimensions, respectively, and 3000 




F55, W56, and Y52 were first assigned in 2D 1H-13C HSQC spectra. Later, aromatic 
hydrogens were matched with the fingerprint and amide- amide regions of 2D TOCSY and 
2D tr-NOESY spectra. 
Sample Preparation and Analysis for 1D Proton Line Broadening and 2D 
Transferred NOESY Experiments 
All NMR experiments were performed at pH 6.5 and at 25 °C. To prevent autolysis, 
the serine protease inhibitor PPACK was added to thrombin at a ratio of 4:1, and the 
mixture was incubated at 37 °C for 30 min. Plasma versions of ProT and PPACK- thrombin 
were buffer exchanged into NMR buffer- [25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, 
(pH 6.5)] using a Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff 
(Sartorius, Göttingen, Germany). Protein concentrations were determined using extinction 
coefficients (E1%280 nm) of 18.3 for thrombin and 13.8 for ProT. Ligand-protein complexes 
with ratios of at least 10:1 were then prepared.  
As is typical for trNOESY experiments, the ligand-protein complex contained a 10-
fold excess of PAR1 (49-62) peptide fragment, and the chemical shifts report on the 
solution environment encountered by the peptide in the presence of the target protein. The 
complexes included 780 M PAR1 (49-62) with 59 M ProT, 900 M PAR1P (49-62) 
with 97 M PPACK-thrombin, 830 M PAR1G (49-62) with 83 M ProT, and 870 M 
PAR1G (44-56) with 87 M PPACK-thrombin. Peptide at a minimum concentration of 1 
mM was used as a free ligand control. 
All NMR experiments in this project were performed on a Varian Inova 700 MHz 
spectrometer with a triple resonance cold probe and pulsed-field Z-axis gradients run at 25 




software). 2D TOCSY, 2D tr-NOESY, and 2D 1H-13C HSQC data were processed using 
NMRPipe and nmrDraw and then further visualized using Sparky.   
1D and 2D 1H-15N HSQC NMR Titration 
ProT and active site inhibited PPACK- thrombin were exchanged into NMR buffer 
using Vivaspin 2 ultrafiltration units with a 5000 Da molecular weight cutoff. A series of 
protein–ligand complexes was then prepared involving PAR fragments PAR1P (49-62), 
PAR1GFD (49-62), PAR1GED (49-62), and PAR1GKE (49-62).  ProT and PPACK-thrombin 
exhibit limited solubility at the high concentrations typically used for NMR titrations. As 
a result, an alternative titration strategy was employed for the current NMR project.   The 
protein concentration typically started in the range of 100-200 μM and was serially diluted 
while maintaining a constant concentration of 15N-labeled ligand. These conditions were 
achieved by removing a certain volume of the protein-ligand solution and replacing it with 
the same volume of the ligand solution. The titrations were thus initiated with a high 
protein: ligand ratio and ended with low protein: ligand ratios all while maintaining a 
constant peptide ligand concentration.  The NMR titrations were therefore monitoring the 
ability of ProT or PPACK inhibited thrombin to bind to the 15N-labeled PAR1 fragment.   
For the first PAR1 binding studies, the starting complexes included 50 M PAR1P (49-
62) with 150 M ProT and 150 M PPACK-thrombin. The serial dilutions for both ProT: 
PAR1P and PPACK-thrombin: PAR1P resulted in ratios that spanned 3:1 to 0.1:1. To 
weaken the affinity of the PAR1P peptide for PPACK-IIa, P54 was replaced with the still 
flexible Glycine. For these PAR1GFD binding studies, starting complexes included 50 M 




for both ProT: PAR1GFD (49-62) and PPACK-thrombin: PAR1GFD resulted in protein-
peptide ratios that spanned 3:1 to 0.1:1.  
To evaluate the electrostatic binding contributions at (pro)- ABE I, a series of acidic 
and basic PAR1 residues were 15N labeled. For the PAR1GED binding studies, the starting 
complexes included 50 M PAR1GED (49-62) with 150 M ProT or PPACK-thrombin. 
The protein:ligand ratio of  ProT:PAR1GEL and PPACK-thrombin: PAR3GEL complexes 
spanned from 3:1 to 0.1:1. For the PAR1GKE binding studies, starting complexes included 
50 M PAR1GKE (49-62) with 150 M ProT and with 185 M PPACK-thrombin. The 
serial dilutions for both ProT: PAR1GKE (49-62) and PPACK-thrombin: PAR1GKE resulted 
in ratios that spanned 3:1 to 0.1:1.  
Parameters for the 1D 1H-15N HSQC titrations for both PAR1P and PAR1G complexes 
included 512 transients, a sweep width of 9000 Hz, and 4096 complex points in the direct 
dimension. Parameters for the 2D 1H-15N HSQC titrations included 16 transients with 64 
complex points in the indirect dimension, sweep widths of 9000Hz for both direct and 
indirect dimensions, and 1242 complex points acquired in the direct dimension. The 15N 
labeled free peptide was used as a control for each titration. 1D 1H-15N HSQC data were 
stacked using Mnova NMR and 2D 1H-15N HSQC data were processed using NMRPipe 
and nmrDraw and then further visualized using Sparky. Quantitative estimates of binding 
interactions between individual 15N-labeled peptide ligand residues and specific proteins 
were determined using in-house scripts written using Python. All the titrations were 
repeated at least twice. A Monte-Carlo approach was employed to calculate the errors in 





1D and 2D 1H-15N HSQC NMR Titration for Long-Range Communication Studies 
 To elucidate whether long-range communication existed between the two exosites 
of thrombin, two PAR based 15N-labeled peptide ligands were chosen that included 
PAR1GED (49-62) and PAR3GEL (44-56). In this titration, triply phosphorylated GpIbα 
(269- 286) is expected to bind at ABE II and 15N-labeled PARs at ABE I. Even though 
GpIbα (269- 286) is reported to have a KD of 5.9 nM for IIa,165 we still made sure that 
GpIbα (269-286) was at least 99.7 % bound during the entire course of the titration. The 
following equation was used to determine the % GpIbα ligand (L) bound to 
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The experimental strategies employed for the NMR titrations were similar to the 
previously described project. The only difference was adding the GpIbα to the thrombin 
prior to starting the PAR titration. For both PAR1GED and PAR3GEL binding studies, the 
starting complexes included 150 M PPACK-IIa, 200 M GpIbα, and 50 M of 15N-
labeled PAR peptide. The protein: ligand ratio of PPACK-thrombin: PAR1GED/PAR3GEL 
complexes spanned from 3:1 to 0.1:1. PPACK- thrombin concentration was diluted from 
150 M to 6 M and GpIbα concentration were diluted from 200 M to 8 M. At each 
titration point, the concentration of 15N-labeled PAR ligands was kept constant. The same 
instrument, parameters, and processing software were used to elucidate long-range 







1D Proton Line Broadening Experiments with PAR1 (49-62) 
1D 1H- NMR experiments were performed for PAR1P (49-62) in the presence and 
absence of enzyme. The appearance of peak broadening can be correlated with particular 
peptide protons that come in direct contact with the enzyme surface. Decent amide proton 
broadening was seen for both PAR1P (49-62) and PAR1G (49-62) in the presence of ProT 
(Figure 37B and 37E). PAR1 residues which had effective line broadening included D50, 
K51, E53, F55, D58, and E60. To rule out that line broadening was only due to the 
increased relaxation effects of higher molecular weight ProT (72 kDa), we also examined 
whether line broadening occurred with lower molecular weight thrombin (37 kDa). The 
further line broadening seen with PPACK-IIa supported the proposal for additional contact 
with the mature exosite (Figure 37C and 37F). Careful examination of the different line 
broadening effects led to the conclusion that PAR1P (49-62) showed better line broadening 
and thus enhanced binding than PAR1G (49-62). Later, individual residues with substantial 
line broadening (D50, K51, E53, F55, D58, and E60) were selected for 15N labeling. 
 2D trNOESY revealed that the PAR1P (49-62) is mostly in an extended 
conformation when bound to ProT (Figure 38A) as evident from having only nearest 
neighbor NOEs. Another feature that was identified was the orientation of the PAR1 Xaa-
Pro bond. NOEs resulting from through space interactions between E53CH and P54CH 
confirmed that the Xaa-Pro adopts a trans conformation when PAR1P (49-62) is bound to 





























15N-HSQC Titration Studies with PAR1PFD (49-62) Labeled at D50 and F55 
 To further evaluate differences in the binding affinities of ABE I directed ligands 
and to decipher exosite maturation, we selected PAR1P (49-62) as our next test PAR 
Figure 38. A) selected NOE cross peaks of PAR1P (49-62) when bound to ProT. B) 
Red pointers indicate NOE between E53CH and P54CH.  
 
Figure 37: Proton line broadening spectra for PAR1P and PAR1G peptides in the presence of prothrombin 
and PPACK-thrombin. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % 
D2O (pH 6.5). A) 1D 1H-NMR spectrum of 1 mM PAR1 (49- 62) peptide in solution B) 1D 1H-NMR 
spectrum of 780 μM PAR1 (49-62) in the presence of 59 μM ProT C) 1D 1H NMR spectrum of 700 μM 
PAR1 (49-62) in the presence of 97 μM PPACK-IIa D) 1D NMR spectrum of 1 mM PAR1G (49- 62) in 
solution E) 1D NMR spectrum of 830 μM PAR1G (49-62) in the presence of 83 μM ProT. F) 1D NMR 





candidate. Results could later be compared with our earlier PAR3 NMR titration studies. 
2D TOCSY and 2D tr-NOESY had been performed on PAR1P to obtain chemical shift 
values for the amide protons of the amino acid residues. Identifying aromatics like W and 
F were however challenging as their side chain protons overlapped in the fingerprint 
region. To increase the accuracy of peak assignments, 1H-13C 2D HSQC was employed 
(Appendix 9). Once all proton chemical shifts were successfully assigned, the best residues 
for 15N labeling were chosen and correlated with the X-ray structures.  
For the first HSQC titration studies, PAR1 D50 and F55 were selected for 15N 
labeling. Figure 36 shows that PAR1 D50 is in ionic interaction with R73 of thrombin and 
F55 is surrounded by the hydrophobic cluster (F34, L65 and I82) of ABE I.49,85 Thrombin 
ABE I is mainly composed of the 30 and 70 loops which are responsible for electrostatic 
and hydrophobic interactions with physiological ligands. HSQC titrations started with 
ProT: PAR1PFD ratios of 2.3:1, where D50 and F55 were 
15N labeled. Unfortunately, the 
[15N]-D50 amide proton was not seen throughout the NMR titration series due to fast 
exchange with the solvent. This amide proton could be detected at pH 3.0, a more acidic 
environment than what ProT/IIa encounters physiologically. By contrast, [15N]-F55 could 
be detected during the full NMR titration series at pH 6.5. 1D HSQC titration revealed that 
the [15N]-F55 peak exhibited line broadening at higher ProT: PAR1PFD ratios and sharper 
peaks started to develop as the enzyme was diluted with a constant amount of 15N- labeled 
PAR1PFD (Figure 39A). 
2D 1H-15N- HSQC cross peaks could be followed for all the titration points of [15N]-
F55 , consistent with this residue being in fast exchange with ProT (Figure 39B). Moreover, 




resulting in a binding affinity (KD) of 99 ± 39.4 µM and a maximal chemical shift 
difference (Δωmax) of 0.47± 0.09 ppm (Figure 39C and Table 4). Upon exosite maturation, 
[15N]-F55 showed extensive line broadening even at the very lower PPACK-IIa: PAR1PFD 
(0.1:1) ratios thus hindering the ability to calculate a KD (data not shown). Such line 

































Figure 39: 1D, 2D 1H-15N HSQC NMR titrations, and KD value of PAR1PFD (49-62) in the presence of ProT. All 
NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of 
PAR1PFD binding studies with ProT, starting complexes included 50 M PAR1PFD (49-62, [15N]-D50, [15N]- F55) in 
at least 115M ProT. The serial dilutions resulted in ProT: PAR1PFD ratios that spanned from 2:1 to 0.1:1. B) 2D 1H-
15N HSQC PAR1PFD binding studies with ProT, starting complexes included 50 M PAR1PFD (49-62, [15N]-D50, 
[15N]- F55) in at least 115M ProT. The serial dilutions resulted in ProT: PAR1PFD ratios that spanned from 2:1 to 
0.1. Representative data sets are shown.  Colors for the HSQC crosspeaks span from blue (highest protein:peptide 
ratio) to red (free peptide). C) Determination of the binding Affinity (KD) for 15N-labeled F55 of PAR1PFD interacting 
with prothrombin. ProT and PAR1P [15N-] F55 led to a KD of 99 ± 39.4 µM. NMR titrations were performed in 
duplicate.  The reported KD values were determined using in-house scripts written using Python. The term |Δδobs| 15N 
ppm = δ15Nbound – δ15N free reflects the absolute difference in chemical shift between the bound and free states of the 
particular 15N-residue. Error analysis was performed using a Monte-Carlo approach assuming a 10% error in the 













IIa residues in 
contact with 
PAR1 (49-62) 




NA F34, L65, I82 





PAR1GFD F55 Too weak 
for NMR 
NA 251 NA F34, L65, I82 





PAR1GED E53 Too weak 
for NMR 
NA Too weak 
for NMR 
NA T74, Y76, and 
R75 
PAR1GED D58 Too weak 
for NMR 
NA 366.6 0.41± 
0.05 
Not seen in X-
ray (might see 
R77a) 
PAR1GKE K51 Too weak 
for NMR 
NA 16749 0.09± 
0.02 
In vicinity of 
R73 
PAR1GKE E60 Too weak 
for NMR 
NA 280 NA Not seen in X-
ray (might see 
I82, K110) 
 
15N-HSQC Titration Studies with PAR1GFD (49-62) Labeled at D50 and F55 
 The strategy to evaluate individual KD values was hindered due to extensive line 
broadening of PAR1PFD [
15N]-F55 when bound to PPACK-IIa. Hence, a weaker binding 
version of PAR1 (49-62) [P54G] was used to probe the availability of (pro)- ABE I for 
binding. A similar P to G substitution had been utilized in our previous PAR3 peptide 
project. The titration was initiated with a 3:1 (ProT: PAR1GFD) protein: ligand ratio where 
D50 and F55 were 15N labeled. Both 1D and 1H-15N 2D HSQC titrations revealed that the 
[15N]-F55 peak showed no change in chemical shift position with ProT (Figure 40A and 
40B) indicating that the new PAR1GFD [
15N]-F55 sequence exhibited less effective 
interactions with the hydrophobic cluster (F34, L65, I82) of zymogen ProT. The 
replacement of PAR1 proline to glycine (P54G) had caused a definite weakening of binding 
Table 4: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR1PFD, 
























Upon exosite maturation, [15N]-F55 did indeed undergo a substantial increase in 
chemical shift during the titration series. The presence of a new binding environment 
around the hydrophobic cluster (F34, L65, I82) of thrombin was thus detected upon ABE 
I maturation (Figure 41A and 41B). Also, the chemical shift changes for [15N]-F55 of 
Figure 40: 1D and 2D 1H-15N HSQC NMR titrations of PAR1GFD (49-62) in the presence of ProT. All 
NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D 
HSQC of PAR1GFD binding studies with ProT, starting complexes included 50 M PAR1GFD (49-62, 
[15N]-D50, [15N]- F55) in at least 150M ProT. The serial dilutions resulted in ProT: PAR1GFD ratios 
that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GFD binding studies with ProT, starting 
complexes included 50 M PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least 150M ProT. The serial 
dilutions resulted in ProT: PAR1GFD ratios that spanned from 3:1 to 0.1. NMR titrations were performed 





PAR1GFD titrations proceeded in the same direction as [
15N]-F55 of PAR1PFD across the 
panels. This common pattern is consistent with the idea that both versions of PAR1 are 
encountering the same environment when bound to PPACK-IIa. The estimated binding 
affinity (KD) of PAR1GFD [
15N]-F55 for PPACK-IIa was 251M (Figure 41C, Table 4). 
The PAR1 P54G sequence was next used to explore binding affinities of other key PAR1 





















Figure 41: 1D, 2D 1H-15N HSQC NMR titrations, and KD value of PAR1GFD (49-62) in the presence of 
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 
6.5). A) 1D HSQC of PAR1GFD binding studies with PPACK-IIa, starting complexes included 50 M 
PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least 150 M PPACK-IIa. The serial dilutions resulted in 
PPACK: PAR1GFD ratios that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GFD binding studies 
with PPACK-IIa, starting complexes included 50 M PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least 
150M PPACK-IIa. The serial dilutions resulted in PPACK-IIa: PAR1PFD ratios that spanned from 3:1 to 
0.1. C) Determination of the binding Affinity (KD) for 15N-labeled F55 of PAR1GFD interacting with 







15N-HSQC Titration Studies with PAR1GED (49-62) Labeled at E53 and D58 
The success in evaluating the binding affinity of a hydrophobic residue ([15N]-F55) 
led to interest in exploring anionic residues which might be involved in effective 
interactions with ABE I of thrombin. Gandhi et al., had previously shown that PAR1 E53 
is involved in hydrogen bonding with thrombin T74 and Y76.49,85  The acidic PAR1 E53 
residue is also in close vicinity of the thrombin ABE I residue R75. Interactions involving 
T74, R75, and Y76 supported our idea of 15N labeling E53 to probe the 70 loop of (pro)- 
ABE I. The published X-ray crystal structures of PAR1 bound to thrombin were unable to 
detect the electron density for the acidic C-terminal tail of PAR1 (58DEEKN62).84  Solution 
NMR would provide an alternative strategy to probe this region of PAR1 by first labeling 
PAR1 D58. 
1D line broadening studies revealed that PAR1 E53 and D58 both showed some 
proton line broadening with ProT. By contrast, both [15N]-E53 and [15N]-D58 did not 
exhibit any chemical shift movement during the full 1D and 2D 15N HSQC titration series 
with ProT.  These results indicated minor interaction with pro-ABE I of ProT but no real 
changes in chemical environment relative to that of free peptide. After ABE I maturation, 
PAR1GED [
15N]-E53 still did not exhibit any change in chemical shift position with 
PPACK-IIa (Figure 42A,42B, 43A and 43B, Table 4). By contrast, the 1D 15N HSQC 
spectra of the PAR1GED [
15N]-D58 peak started to show line broadening and an upfield 
chemical shift already at higher PPACK-IIa: ligand ratios. This effect was confirmed with 
2D HSQC spectra, where changes in chemical shift position for PAR1GED [
15N]-D58 were 
clearly observed for the 4:1 to 1:1 PPACK-IIa to PAR1GED ratios. This result provided 




be defined by X-ray crystallography. The NMR titration series revealed that PAR1GED 
[15N]-D58 is likely in fast exchange with PPACK-IIa with KD of 38 ± 6.6 µM and a 
maximal chemical shift difference (Δωmax) of 0.41± 0.05 ppm (Figures 42A, 42B, 43B and 


































Figure 42: 1D HSQC NMR titrations of PAR1GED (49-62) in the presence of ProT and PPACK-
IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 
6.5). A) 1D HSQC of PAR1GED binding studies with ProT, starting complexes included 50 M 
PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M ProT. The serial dilutions resulted in 
ProT: PAR1GED ratios that spanned from 3:1 to 0.2:1. B) 1D HSQC of PAR1GED binding studies 
with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in 
at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that spanned 




































15N-HSQC Titration Studies with PAR1GKE (49-62) Labeled at K51 and E60 
The NMR mapping studies moved on to explore the binding affinity of a basic 
residue and a second acidic residue within the N-terminal region of PAR1 (49-62). A 
careful review of the PAR1 (49-62) – IIa X-ray structure (Figure 35) showed that K51 is 
Figure 43: 2D 1H-15N HSQC NMR titrations of PAR1GED (49-62) in the presence of ProT and 
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % 
D2O (pH 6.5). A) 1H-15N 2D HSQC of PAR1GED binding studies with ProT, starting complexes 
included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M ProT. The serial 
dilutions resulted in ProT: PAR1GED ratios that spanned from 3:1 to 0.2:1. B) 1H-15N 2D HSQC of 
PAR1GED binding studies with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62, 
[15N]-E53, [15N]- D58) in at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK: 
PAR1GED ratios that spanned from 4:1 to 0.1:1. C) Determination of the binding Affinity (KD) for 
15N-labeled D58 of PAR1GED interacting with PPACK-IIa led to a KD of 38 ± 6.6 µM. NMR 





in close vicinity of IIa ABE I residues R73 and T74. A second acidic residue from the C-
terminal segment of PAR1G (49-62) was also chosen for analysis. Like D58, the E60 
residue was missing from the thrombin- PAR1 X-ray crystal structure.85  Both [15N]-K51 
and [15N]- E60 did not show any change in chemical shift position in the presence of ProT 
indicating little if any interaction with pro-ABE I (Figure 44A and 45A). However upon 
exosite maturation, the 2D HSQC studies revealed that PAR1 residue K51 showed modest 
changes in chemical shift in the hydrogen dimension with a KD of 167 ± 49.2 µM (Δωmax 
= 0.09 ± 0.02) and for PAR1 E60 a KD of 280 µM in the nitrogen dimension (Figure 44B, 
45B and 46A and 46B, Table 4). Overall, both [15N]-K51 and [15N]- E60 had weak 


























Figure 44: 1D HSQC NMR titrations of PAR1GKE (49-62) in the presence of ProT and PPACK-
IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 
6.5). A) 1D HSQC of PAR1GKE binding studies with ProT, starting complexes included 50 M 
PAR1GKE (49-62, [15N]-K51, [15N]- E60) in at least 150M ProT. The serial dilutions resulted in 
ProT: PAR1GKE ratios that spanned from 3:1 to 0.1:1. B) 1D HSQC of PAR1GKE binding studies 
with PPACK-IIa, starting complexes included 50 M PAR1GKE (49-62, [15N]-K51, [15N]- E60) 
in at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that 

















































Figure 45: 2D 1H-15N HSQC NMR titrations of PAR1GKE (49-62) in the presence of ProT and 
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % 
D2O (pH 6.5). A) 2D 1H-15N HSQC of PAR1GKE binding studies with ProT, starting complexes 
included 50 M PAR1GED (49-62, [15N]-K51, [15N]- E60) in at least 150M ProT. The serial 
dilutions resulted in ProT: PAR1GKE ratios that spanned from 3:1 to 0.1:1. B) 2D HSQC of 
PAR1GKE binding studies with PPACK-IIa, starting complexes included 50 M PAR1GKE (49-
62, [15N]-K51, [15N]- E60) in at least 150 M PPACK-IIa. The serial dilutions resulted in 
PPACK: PAR1GKE ratios that spanned from 3:1 to 0.1:1. NMR titrations were performed in 
duplicate.  
 
Figure 46: Determination of the binding Affinity (KD) for 15N-labeled K51 and E60 of PAR1GKE 
interacting with PPACK-IIa led to a KD of 167 ± 49.2 µM and 280 µM respectively. NMR titrations were 
performed in duplicate.  The reported KD values were determined using in-house scripts written using 
Python. The term and Δδobs| 1H ppm = δ1Hbound – δ1H free reflects the absolute difference in chemical shift 






1D and 2D 1H-15N HSQC NMR Titration for Long-Range Communication Studies 
 Previously published HDX-MS experiments from our lab demonstrated that when 
a triply phosphorylated GpIb (269-282) peptide bound to thrombin ABE II, there was a 
long-range influence over to the ABE I region.60,78  To further characterize this dual ligand 
binding system, NMR titration studies were carried out with complexes consisting of 
unlabeled GpIb (269-282), PPACK-IIa, and two distinct 15N- labeled PAR based 
peptides. PAR1GED and PAR3GEL were selected for this study. Our previous HSQC 
titrations had shown that both of these PAR peptides could document information about 
the maturation of the 30 and 70 loops of thrombin.  
The following experimental strategies were carried out to monitor dual ligand 
allostery. Prior to the titration, a saturated amount of triply phosphorylated GpIb (269-
282) was added to PPACK-IIa followed by the desired 15N-labeled PAR peptide. Both 
GpIb and PPACK-IIa were then serially diluted with constant amounts of 15N- labeled 
peptide. The same ratios of PPACK IIa - PAR1 and PPACK IIa-PAR3 were maintained as 
in the single ligand experiments described earlier. Interestingly, titrations with PAR1GED 
revealed that E53 went from an affinity for thrombin ABE I that was too weak to detect by 
NMR to one with an improved KD of 125 ± 36 µM (Δωmax = 0.32 ± 0.05) in the presence 
of GpIbα peptide (Figure 42B, 43B, 47A, 47B, 48A, Table 4 and Table 5). By contrast, 
PAR1 D58 did not respond much to the presence of GpIb binding at ABE II.  The KD for 
D58 went from 36 ± 6.6 µM (Δωmax = 0.41 ± 0.05) to 75 ± 14.9 µM (Δωmax = 0.52 ± 0.05) 
(Figure 42B, 43B, 47B and 48B, Table 4 and Table 5).  
The PAR3GEL peptide displayed a more dramatic response to GpIbα binding at 




KD of 124 µM and E48 had a KD of >200 µM.  With GpIbα binding to ABE II, the PAR3 
peaks broadened so much there were insufficient data pints for calculating the KD values.  
PAR3GEL had entered into the tighter binding intermediate exchange regime.  From these 
studies, NMR could document long range influence from thrombin ABE II over to ABE I.  































Figure 47: 1D and 2D 1H-15N HSQC NMR titrations of PAR1GED (49-62) in the presence of 
saturated amounts of GpIba (269-282) and PPACK-IIa . All NMR samples were in 25 mM H3PO4, 
150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of PAR1GED binding studies 
with PPACK-IIa, starting complexes included 50 M PAR1GFD (49-62, [15N]-E53, [15N]- D58) in 
at least 150M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that spanned 
from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GED binding studies with PPACK-IIa, starting 
complexes included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M PPACK-





















Figure 48: Determination of the binding Affinity (KD) for 15N-labeled E53 and K51 of PAR1GED 
interacting with GpIba (269-282) + PPACK-IIa led to a KD of 125 ± 36 µM and KD of 75 ± 14.9 
µM respectively. NMR titrations were performed in duplicate.  The reported KD values were 
determined using in-house scripts written using Python.  
 
Figure 49: 1D, and 2D 1H-15N HSQC NMR titrations of PAR3GEL (44-56) in the presence of 
saturated amounts of GpIba (269-282) and PPACK-IIa. All NMR samples were in 25 mM 
H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of PAR3GEL 
binding studies with PPACK-IIa, starting complexes included 50 M PAR3GEL (44-56, [15N]-
E48, [15N]- L52) in at least 150M PPACK-IIa. The serial dilutions resulted in PPACK: 
PAR3GEL ratios that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR3GEL binding 
studies with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62, [15N]-E48, 
[15N]- L52) in at least 150M PPACK-IIa. The serial dilutions resulted in PPACK-IIa: 









IIa residues in 
contact with PAR1 
(49-62) 
PAR1GED E53 Too weak for 
NMR 
NA In vicinity of T74, 
R75, and Y76 
PAR1GED+GpIb E53 12636 0.32 ± 
0.05 
In vicinity of T74, 
R75, and Y76 
PAR1GED D58 366.6 0.41± 
0.05 
Not seen in X-ray 
(might see R77a) 
PAR1GED+GpIb D58 7515 0.52 ± 
0.05 
Not seen in X-ray 
(might see R77a) 
 













47 ± 6  1.84± 0.08 F34, L65, I82 






Too tight for NMR Insufficient 
data points 
R75 





Thrombin is a multifunctional serine protease that is originally derived from the 
zymogen Prothrombin. Besides the thrombin active site region, ligands and substrates also 
can bind to the regulatory anion binding exosites ABE I and II.  PAR1 and PAR3 both have 
segments that target ABE I thereby providing a second anchoring point on to the thrombin 
surface.  PAR1 and PAR3 can use their ABE I binding capabilities to help promote 
thrombin dependent cleavage of PAR4.86,166  Once activated, PARs help in platelet 
activation, platelet aggregation, and triggering inflammatory processes.    
Table 5: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR1GED 
when bound to GpIb+PPACK-IIa and PPACK-IIa 
 
Table 6: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR3GEL 





An important goal of the current project was to characterize the diversity of ligand 
binding interactions that exists as PAR residues bind to zymogen ProT versus mature 
thrombin.  New studies with PAR1 peptides were carried out and later compared with our 
previously published PAR3 titrations when bound to ProT and PPACK-IIa.154  Because 
GpIb can function as a cofactor for PAR1 hydrolysis by thrombin, we also wanted to 
explore the conformational features of the ternary GpIb-IIa-PAR1 complex. While 
saturated amounts of GpIbα peptide interacted at ABE II, binding affinities of ABEI-
directed PAR1 (49-62) and later PAR3 (46-52) were probed. All our experiments were 
carried out with active site inhibited thrombin to eliminate autolysis from occurring during 
the long NMR titration experiments. Prior NMR relaxation studies proved that 
communication can still exist between the active site and ABE I when the active site is 
inhibited with PPACK.133-135  For all NMR experiments, pH was maintained at 6.5 to avoid 
extensive amide proton exchange with solvent.  
1D 1H line broadening studies revealed that PAR1P (49-62) and PAR1G (49-62) 
showed moderate line broadening with ProT, and the line broadening increased upon 
formation of mature thrombin (Figure 37A-F). Weaker line broadening was observed for 
PAR1G (49-62), containing a P54G substitution, thus suggesting this modified PAR1 
sequence would work, if needed, as a lower affinity version of PAR1 (49-62). A similar 
strategy had been employed for our previous PAR3G project.154 
PAR1 peptides were synthesized with 15N amide labeling at D50, K51, E53, F55, 
D58, and E60.  The first two residues examined included F55 and D50.  The 15N-D50 of 
PAR1P (49-62) forms an ionic pair with thrombin R73, an important residue of the 70 loop 




I8249,85. Unfortunately, the [15N]-D50 amide proton was in fast exchange with the 10% 
D2O found in the solvent and was never visible during the course of the NMR titration 
series at pH 6.5. More success occurred with the PAR1P F55 residue. NMR titrations 
revealed that [15N]-F55 was in fast exchange with the ProT protein surface and had a 
binding affinity of 99 ± 39.4 M. These results indicated that pro-ABE I is already 
available for hydrophobic interactions with the PAR1P peptide (Figure 39A-C, Table 4). 
The same [15N]-F55 exhibited extensive peak broadening when bound to PPACK- IIa due 
to increased affinity to mature ABE I.  
The fact that [15N]-F55 appeared to be in intermediate exchange with PPACK-IIa 
was a major hindrance to the project since KD values could not be determined. To address 
this issue, the P54G replacement was chosen to help generate a weaker binding PAR1 
peptide defined as PAR1G. Subsequent 1H-15N HSQC titration studies revealed that [15N]-
F55 of PAR1GFD now made only modest interactions with ProT (Figure 40A and 40B) and 
affinity was too weak to calculate a KD. This result contrasts with the [
15N]-L52 of 
PAR3GFD which shares common hydrophobic interactions with thrombin residues (F34, 
L65, and I82) (Figure 50). The KD for PAR3GEL [
15N]-L52 binding to ProT was 124 M. 
See Chapter 3 for a summary of all KD values determined from our previous work with 
15N 
labeled PAR3 residues.154 
Following ProT to thrombin maturation, [15N]-F55 of PAR1GFD exhibited greater 
interactions with PPACK- IIa and was now in fast exchange with the ABE I surface. The 
broad range of chemical shifts occurring during the NMR titration is consistent with 
PAR1GFD [
15N]-F55 encountering a new binding environment. The PAR1 P54G 




the binding affinity KD was 251 M (Figure 41A- 41C, Table 4). These studies indicate 
that an improved binding environment for F55 of PAR1GFD is generated when pro-ABE I 
on ProT is converted to ABE I on thrombin.  However, this F55 does not exhibit strong 
stabilizing interactions with ABE I. By contrast, the L52 in PAR3GEL had a KD of 47 M 
towards PPACK-IIa.154  The interactions with thrombin hydrophobic cluster (F34, L65, 










As NMR is an excellent technique to probe the binding affinities of residues which 
are in fast exchange, we next selected E53 and D58 for 15N labeling. PAR1 E53 is involved 
in hydrogen bonding with thrombin Y76 and T74 and is also in proximity to thrombin 
R7549,85. PAR1 D58 is the first residue of a flexible acidic C-terminal tail of PAR1 (49-62) 
that has not been detected in X-crystal structures. The 1H-15N HSQC titrations studies 
revealed that [15N]-E53 of PAR1GED showed no substantial interaction with either ProT or 
PPACK-IIa (Figure 42A, 42B, 43A and 43B). This E53 effect might be worsened because 
of replacement of the adjacent PAR1 Pro54 with Gly (P54G).  As a result, E53 may be 




hindered from adopting a proper orientation to promote effective interactions with (pro)-
ABE I. By contrast, PAR3 E48 is known to participate in a neighboring electrostatic 
interaction with ABE I R75.  Binding affinities went from a KD value of >200 uM for ProT 
to a too tight to calculate by NMR for thrombin (See Chapter 3).  
Next, PAR1 D58 which is part of the acidic C-terminal tail segment provided 
valuable, new mapping information. The [15N]-D58 of PAR1GED did not detect significant 
interactions with ProT. However, upon exosite maturation, [15N]-D58 was in fast exchange 
with PPACK-IIa yielding a KD of 36 ± 6.6 M. (Figure 42A, 42B, 43A, 43B and 43C, 
Table 4) Our NMR titration results thus provided the first solution-based evidence for D58 
making direct contact with ABE I. Effective binding interactions occurred with the 
thrombin surface and a new chemical environment was encountered.   
An alignment of PAR3 and PAR1 residues suggests that PAR1 D58 might be near 
to thrombin R77a (Figure 50). Consequently, thrombin R77a may help to stabilize PAR1 
D58 like the strong electrostatics seen between PAR3G D54 and IIa R77a.  With the PAR3 
peptide, D54 exhibited a KD of 65 ± 12 µM with immature ProT and the affinity became 
too tight to calculate with mature thrombin ABE I.154  Future mutations to thrombin ABE 
I may help confirm the key thrombin residues involved in binding of PAR1 D58.     
So far, the NMR titrations studies have focused on hydrophobic and acidic residues. 
To check whether a basic residue of PAR1 can interact with ABE I, PAR1 K51 which is 
in the vicinity of thrombin R73 and T74 was selected.49,85  To probe another residue from 
the PAR1 C-terminal tail, E60 was chosen. Both [15N]-K51 and [15N]-E60 did not show 
significant interactions with ProT (Figures 44A and 45A). Later upon exosite maturation, 




undergo movement in chemical shift (KD = 167 ± 49.2 M, Figure 46A, Table 4). These 
observations highlight NMR as a sensitive technique to explore environments around 
different atoms such as hydrogen and nitrogen. Like PAR1 K51, the acidic C-terminal 
PAR1 residues [15N]-E60 showed a binding interaction too weak to quantitate by NMR for 
ProT that later increased to a measurable KD of 280 µM with mature PPACK-thrombin. 
(Figure 44A, 44B, 45A, 45B, and 46B, Table 4). With these NMR titrations results, a 
second residue within the X-ray invisible region could be probed.  Both PAR1 acidic 
residues D58 and E60 could document contact with thrombin ABE I, but the affinities 
indicate that D58 is better anchored to ABE I than E60. In comparison to PAR1 E60, the 
PAR3 E56 contacts thrombin I82 and K110. Additional NMR mapping studies are needed 
to assess how the full C-terminal region of PAR1 interacts with thrombin ABE I. The 
flexibility of this PAR1 tail might have hindered the ability to promote greater binding 
affinity. 
From our 1H-15N-HSQC titration series, we can conclude that all 15N-labeled 
residues of PAR1G (49-62) showed little or no interaction with ProT. However, upon 
exosite maturation, interactions with PPACK-IIa increased with KD values ranging from 
36 to 280 M. Interestingly, the previously published PAR3G residues were, better at 
binding the immature pro-ABE I region of thrombin than the PAR1 residues.154  After 
determining individual binding affinities of labeled residues in both PAR1 (49-62) and 
PAR3 (44-56), we proceeded further to explore whether binding of GpIb at ABE II would 
influence the affinities of ABE I ligands.  
Allosteric communication between exosites and the active site is an important step 




between the exosites is less well explored.58,164  Physiologically, GpIb bound to thrombin 
ABE II helps in activating the ABE I directed ligand PAR1.80  In addition, allowing 
zymogen fragment F2 to bind to thrombin ABE II reduces the conversion of fibrinogen to 
fibrin.167  The first direct evidence for direct allosteric communication between the exosites 
was reported by Weitz et al using F2 as the ABE II directed ligand and Hirudin as the ABE 
I directed ligand.58,164,168  However, Bock et al., cautioned that changes in affinity could be 
due to competitive overlapping binding sites or additional interactions between the ligands 
themselves.59 
To further decipher long-range allosteric communication in thrombin, a triply 
phosphorylated GpIbα (269-282) was used in this project as the ABE II ligand and PAR 
peptides would target ABE I.  With the GpIbα- PPACK-IIa complex, an increased affinity 
of [15N]-E53 towards ABE- I was observed. (Figure 47A, 47B, 48A, 48B, Table 4, and 
Table 5). The non-optimal orientation of E53 binding to ABE I may have been overcome 
by the introduction of GpIbα. By contrast, GpIbα did not have much of an effect on the C-
terminal PAR1 residue D58 as evident from the modest change in KD that occurred after 
taking error limits into account (Figure 47A, 47B, 48A, 48B, Table 4, and Table 5). 
Titration with PAR3GEL revealed that PAR3 [
15N]-E48 and [15N]-L52 both exhibited 
extensive peak broadening already at low PPACK-IIa: PAR3GEL ratios (Figure 49A and 
49B). The affinity of PAR3 [15N]-L52 for ABE I went from 47 ± 6 M to too tight to 
calculate in the presence of ABE II ligand GpIbα. PAR3 [15N]-E48 continued to remain 
too tight to calculate even in the presence of GpIbα. Once gain GpIbα can influence 




When aligning the PAR3 and PAR1 sequences, GpIbα binding is shown to have 
influenced the conformation of a set of thrombin residues (Figure 50). PAR3 E48, PAR3 
L52, and PAR1 E53 all underwent increased affinity in the presence of GpIbα-thrombin. 
The corresponding thrombin residues that interact with these PAR residues can be clustered 
as (F34, L65, I82) and (T74, R75, Y76). In support of the current NMR titrations, HDX-
MS studies previously reported that GpIbα binding exerts a long-range solvent accessibility 
effect over to the thrombin 65-84 ABE I region.60  Future studies could probe how GpIbα 
influences additional PAR1 and PAR3 residues. Unlike the PAR3 and PAR1 residues 
mentioned above, the more C-terminal PAR1 D58 which had the best PAR-thrombin KD 
value was less affected by GpIbα binding. PAR1 D58 is postulated to bind in the vicinity 
of thrombin R77a. Binding of GpIbα at thrombin ABE II may not further promote 
interactions between thrombin ABE I R77a and PAR1 D58. 
Overall, we conclude that although PAR1 and PAR3 both target similar areas of 
the thrombin 30 and 70 loop regions the individual PAR amino acids make unique 
contributions to the overall binding affinities. Furthermore, our novel NMR titration 
approach allowed us to probe such distinctions compared with previously published PAR3 
(44-56) 1H-15N-HSQC titration results.154  PAR1G (49-62) exhibited weaker interactions 
with ProT. These results suggest that drugs that mimic PAR1G interactions may be less 
inclined to target immature pro-ABE I.  By contrast, PAR3G interactions are tighter and 
could already bind to immature pro-ABE I. As a result, therapeutics based on PAR3G could 
help block the maturation of active thrombin. Finally, NMR studies involving the ternary 
complex GpIbα – PPACK-IIa -PAR1/3 provided strong evidence that GpIbα binding can 




the future, the new knowledge gained from this project may help in development of drug 






SECONDARY STRUCTURE INFORMATION AS A CLUE TO EXPLAIN THE 




Thrombin utilizes an active site region and two exosites ABE I and ABE II to 
initiate and regulate its functions. The serine protease activity of thrombin is supported by 
a catalytic triad composed of D102, H57, and S195 (Figure 51A).37,169  Thrombin substrate 
specificity is controlled by the 60s loop also known as the β-insertion loop (residues Y60a-
K60f). Two critical 60s loop residues that limit substrate entrance into the active site 
include Y60a and W60d (Figure 51A). Other important thrombin residues that help 
accommodate substrates are part of the aryl binding pocket and include W215, I174, and 
L99 (Figure 51A). Following substrate binding at the active site, thrombin cleaves the 
substrate scissile bond (R/K-X) designated by the P1-P1' nomenclature.61  Substrate amino 
acids N-terminal of the hydrolysis site are labeled P2, P3, P4 etc. whereas those that are C-
terminal are labeled P2', P3', P4' etc. The substrate residue at the P1 position (R or K) forms 
a salt bridge with thrombin D189 at the bottom of the active site cleft. The P2 residue makes 
extensive contacts with the 60s loop, the P4 interacts with the aryl binding site, and P3 is 





34VVPR37) of the FXIII Activation Peptide and critical residues of 
thrombin.71 
 
A key procoagulant activity of the serine protease thrombin is to convert fibrinogen 
(Fbg) into fibrin. Fibrinogen (340kDa) is the most abundant coagulation protein in the 
blood, and it consists of six polypeptide chains, two each of the Aα, Bβ, and γ chains.30,33,36 
The N-terminal ends of all six chains meet at the central E region, and the C-terminal ends 
meet at the two peripheral D regions. Thrombin first cleaves at the R16-G17 peptide bond 
of the Fbg Aα chain to release Fibrinopeptide A (FpA) (Figure 52). This cleavage helps in 
formation of half-staggered, double stranded protofibrils involving D:E:D interactions. 
Later thrombin cleaves at the R14-G15 peptide bond of the Fbg Bβ chain to release 
Fibrinopeptide B (FpB).34,63,170 
Once both peptides are released, transglutaminase FXIIIa helps in cross linking 
fibrin protofibrils through isopeptide bond formations.171  Steady-state kinetic studies of 
thrombin-catalyzed hydrolysis of fibrinogen revealed that release of FpA follows a first- 
A 
Figure 51:X-ray crystal structure of thrombin highlighting key residues that surround the active 
site.A) Ribbon diagram of thrombin (gray) showing selected residues as colored sticks (PDB ID: 
1DE7). Residues include the catalytic triad (red), Y60a and W60d (purple), L99 and I174 (blue), 
W215 and E217 (green). B) The enzyme-bound FXIII AP segment (orange) (P4-P1) surrounded by 














order reaction. Interestingly, initial release of FpB is slow and the rate of FpB release is 












Mutations have been identified that involve fibrinogen Bβ chain residues or that 
influence this chain.173,174  Fibrinogen Ijmuiden (R14C) and Fibrinogen Nijmegen (R44C) 
mutations are common in patients with thrombophilia and have been associated with 
defective fibrin polymerization.175  The F8Y mutation in the fibrinogen Aα chain leads to 
preferential cleavage of Fbg Bβ over Fbg Aα.176  The X-ray crystal structure of the Fbg Aα 
F8Y mutant revealed that the carbonyl oxygen of Y8 shifted 1.8Å relative to the original 
carbonyl oxygen of F8 leading to distortion of the scissile bond. As a result, the release of 
FpA becomes greatly hindered.  
Unexpectedly when fibrinogen is adsorbed on surfaces like glass, carbon, 
polyethylene, and polystyrene, it takes on two kinds of orientations. One is “side-on” 
Figure 52: Fibrin clot formation is initiated by the cleavage of FpA leading to the formation 
of protofibrils, next the cleavage of FpB results in lateral aggregation of fibrin. Finally, FXIIIa 
imparts isopeptide bonds between two fibrin molecules there by stabilizing fibrin 





(laying on the surface) occurring at low fibrinogen concentration and the other is “end-on” 
(standing on the surface) at high fibrinogen concentration.177  For each orientation, only a 
portion of fibrinopeptides are accessible for thrombin cleavage. In the “side-on” 
orientation, 36% of FpA and 35% of FpB are released, whereas in the “end-on” orientation, 
37% of FpA and a higher 64% of FpB is released. 
Over the years, researchers have further explored the initial steps of fibrin 
formation. Using recombinant fibrinogen proteins, Mullin et al., suggested that thrombin 
specificity is what dictates the order of fibrinopeptide release.178  Based on modeling 
studies of the N- terminal ends of both the Aα chain and the Bβ chains, Pechik et al 
predicted that it is the length and orientation of the chains that lead to the weaker kinetics 
of FpB release.170  Brummel et al., made the critical observation that release of FpA and 
activation of FXIII occur simultaneously, thus allowing FXIIIa to first cross-link the γ- 
chains in the newly formed fibrin protofibrils.179  Later when FpB is released by thrombin, 
the fibrinogen αC domains become exposed and FXIIIa is responsible for additional α-α, 
α-γ, and higher order crosslinking of protofibrils (Figure 52). 
All the work discussed above has been done with different lengths of Fbg Aα and 
Bβ chains. None of them could provide information on the structural features of the Fbg 
Bβ segment that comes in direct contact with thrombin. Such Fbg Bβ interactions will 
dictate the orientation of the substrate- enzyme complex and thus control the ability of 
thrombin to cleave the FpB sequence. An important focus of the chapter was to determine 
individual kinetic parameters for thrombin- catalyzed hydrolysis of Fbg Bβ (5-16). The 
kinetic parameters obtained were compared with other thrombin substrates including FXIII 




the conclusion that Fbg Bβ (5-16) had the lowest kcat/Km value thereby making it rather a 
poor substrate for thrombin. Solution NMR was employed to elucidate the structural 
features behind the weak cleavage of Fbg Bβ (5-16). Unlike FXIII AP (28-41) V34F, Fbg 
Bβ (5-16) does not appear to take advantage of the aromatic Phenylalanine (F) at P4 and P5 
positions to promote improved binding interactions with thrombin. Another striking reason 
behind the poor kinetics is probably the smaller Alanine residue at the P2 position that 
cannot serve as an additional anchor point below the thrombin 60s loop. 
 
MATERIALS AND METHODS 
Materials 
Bovine thrombin was purchased from Haematologic Technologies, Inc (Essex 
Junction, VT). Human recombinant thrombin was a generous gift from Dr. Enrico Di Cera 
and Ms. Leslie Pelc, Saint Louis University, St. Louis, MO. D2O (99.96%) was from 
Cambridge Isotope Laboratories (Andover, MA).                                                                                                  
Synthetic peptide 
Fbg Bβ (5-16) was synthesized by New England Peptides (Gardner, MA). The 
amino acid sequence of this peptide is as follows: (Ac-DNEEGFFSARGH-Amide). The 
purity of Fbg Bβ (5-16) was verified by high-performance liquid chromatography and 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Initial stock 
solutions of peptide were solubilized in deionized water. The peptide was completely 
soluble at pH 7.0, and the concentrations were determined by quantitative amino acid 





Sample preparation for HPLC based kinetic assay 
 The HPLC based kinetics assay of Trumbo et al., was employed.69  Briefly, a 6-7 
mM peptide stock solution was prepared. Later, the peptide solution was diluted into assay 
buffer (50 mM H3PO4,100 mM NaCl, 0.1% PEG, pH 7.4) and heated to 25 °C in a heat 
block. The final concentrations of the Fbg Bβ (5-16) substrate spanned from 100 to 1500 
µM. Hydrolysis of Fbg Bβ (5-16) at the R14-G15 peptide bond was initiated with the 
addition of 134 nM of recombinant human thrombin. An aliquot of the reaction mixture 
was removed at 3, 5, 7, 9, 11, 13 and 17 mins and then quenched with 12.5% H3PO4. For 
all kinetic assay runs, ≤ 15% of the substrate Fbg Bβ (5-16) was cleaved by thrombin to 
release the product FpB (5-14). Quenched reaction time points were analyzed by RP-HPLC 
using a Waters X-Bridge BEH130 C18 5µm column on a Waters 2695 HPLC system. 
Peaks for the substrate Fbg Bβ (5-16) and the resultant product FpB (5-14) were separated 
using an acetonitrile based gradient of [15% CH3CN, 0.09% trifluoroacetic acid in dI 
water] to [50% CH3CN, 0.09% trifluoroacetic acid in dI water]. Product peak areas were 
converted to concentration using calibration curves constructed for Fbg Bβ. The slopes of 
product concentration versus time plots were used to determine the initial velocities (in 
μM/s) for the different thrombin-catalyzed reactions. The kinetic experiments were done 
in triplicate, and kinetic constants were determined following nonlinear regression analysis 
fits to the equation. V =Vmax/ (1 + Km/[S]) in Kaleidagraph (Synergy). The kcat values were 
calculated by knowing the Vmax values and a final thrombin concentration of 134 nM.  
Sample preparation for solution NMR experiments 
All NMR experiments were performed at pH 5.6. Bovine plasma thrombin was 




5.6)] using a Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff 
(Sartorius, Göttingen, Germany). Thrombin concentration was determined using an 
extinction coefficient (E1%280 nm) of 18.3 and a MW of 36,500 g/mol. For our 1D and 2D 
1H NMR based studies, ligand-protein complexes with ratios of at least 10:1 were then 
prepared. The complexes included 1600 M Fbg Bβ (5-16) and 160 M thrombin. Fbg Bβ 
at a minimum concentration of 1.5 mM was used as a free ligand control.  
NMR experiments were then performed at 25 °C on a Varian Inova 700 MHz 
spectrometer with a triple resonance cold probe and pulsed-field Z-axis gradients. Proton 
chemical shift values for all the Fbg Bβ amino acid residues were determined using a 
combination of 2D TOCSY and 2D-transferred NOESY spectra. Standard TOCSY and 
NOESY pulse sequences were employed. Parameters for the 2D NMR experiments 
included nt=16, ni=512, np= 2486, gain= 20 and sweep widths of 7022.5 Hz for both direct 
and indirect dimensions. A mixing time of 400 msecs was employed for the 2D tr-NOESY. 
The 1D 1H NMR spectra were processed using Mnova NMR (Mestrelab Research 
software). 2D TOCSY and tr-NOESY data were processed using NMRPipe and nmrDraw 
and then further visualized using Sparky.  
 
RESULTS 
Thrombin-catalyzed release of Fibrinopeptide B 
An HPLC based kinetic assay was employed to determine the individual kinetic 
constants associated with hydrolysis of Fbg Bβ (5-16) by human recombinant thrombin. 
Thrombin cleaves Fbg Bβ at the R14-G15 peptide bond releasing peptide fragment (5-14). 




eluted first from the C18 column followed by the product (5-14). This elution order 
occurred because all the HPLC-based kinetic assays were done using an acetonitrile 
gradient with 0.09% trifluoroacetic acid. This acidic solution environment makes substrate 
Fbg Bβ (5-16) more hydrophilic (+2 charge) than the product FpB (5-14) (+1 charge). The 











Figure 53 corresponds to a representative 500 M Fbg Bβ (5-16) kinetic reaction. 
The product peak area increased over the course of the 0-17 min reaction time. Peaks 
neighboring the product FpB 5-14 corresponded to contaminants found in the 90% pure 
synthetic peptide. To allow for kinetic parameter determination, the substrate 
concentrations then spanned from 100 to 1500 M Fbg Bβ (5-16). Non-linear regression 
analysis methods were used to calculate Km, kcat, and kcat/ Km values for the hydrolysis of 
Fbg Bβ (5-16). With human recombinant thrombin, the kinetic parameters included a Km 
Figure 53: Hydrolysis of Fbg Bβ (5-16) as a function of incubation time. 500 µM Fbg Bβ (5-16) 
was hydrolyzed by 130 nM thrombin for 3, 5, 7, 9, 11,15 and 17 mins. Each quenched time point 
was run on a C18 column using a Waters HPLC system. A linear gradient of 15% acetonitrile, 0.09% 
trifluoroacetic acid in water to 50% acetonitrile, 0.09% trifluoroacetic acid in water in 20 min at a 
flow rate of 0.5 ml/min was employed. The original substrate peptide Fbg Bβ (5-16) eluted at 
approximately 4.6 mins whereas the hydrolyzed product FpB (5-14) eluted at approximately 5.7 
mins.  
 
Product peak (5-14) 




of 1271 ± 154 µM, a kcat of 1.0 ± 0.075 s
-1, and a kcat/ Km of 8.2x10
-4 ± 1.2x10-4 s-1 µM-1 
(Table 7 and 8).  
Table 7: Human substrate sequences that target the thrombin active site region.  indicates 




Fibrinogen Bβ (5-16)                                  5D N E E G F F S A R  G H16 
Fibrinogen Aα (7-20)                                   7D F L A E G G G V R  G P R V20                                               
Factor XIII (28-41) V34 AP                         28T V E L Q G V V P R  G V N L41 
Factor XIII (28-41) V34F AP                     28T V E L Q G F V P R  G V N L41 
Factor XIII (28-41) V34W AP                     28T V E L Q G W V P R  G V N L41 
Factor XIII (28-41) V34L AP                   28T V E L Q G L V P R  G V N L41 
PAR1 (29-45)                          29K A T N A T L D P R  S F L L45 




Table 8: Kinetic constants for the hydrolysis of Arg-Xaa by thrombin 
________________________________________________________________________ 
Substrate peptides                              Km (µM)           kcat (s
-1)            kcat/ Km (s
-1 µM-1) 
________________________________________________________________________ 
Fibrinogen Bβ (5-16)a                    1271 ± 154        1.0± 0.075        8.2x10-4 ± 1.2x10-4 
Fibrinogen Aα (7-20)62                    569 ± 76         31.0 ± 0.005      5.5x10-2 ± 7.0x10-3 
FXIII (28-41) V34 AP62                  298 ± 42           2.6 ± 0.005      8.6x10-3 ± 1.0x10-3 
FXIII (28-41) V34L AP62               315 ± 42         23 ± 0.003         7.3x10-2 ± 1.2x10-3 
FXIII (28-41) V34F AP180              442 ± 93           6.3 ± 0.54        1.4x10-2 ± 3.0x10-3 
FXIII (28-41) V34WAP181              637 ± 56           7.6 ± 0.3          1.2x10-2 ± 1.2x10-3 
PAR1 (29-45)64                                900        35                       4.0x10-2 
PAR4 (38-51)65                               113 ± 19        10.2 ± 0.8           9.0x10-2 ± 1.7x10-2 
________________________________________________________________________ 
aThe results shown here represent averages of at least three independent experiments. Kinetic values were 
calculated using nonlinear regression analysis methods using Kaleidagraph. The error values correspond to 
standard error of the mean (SEM).  
 
Solution NMR studies of free and thrombin bound FpB (5-16)  
 Chemical shift assignments for all the Fbg Bβ residues were derived from 2D 
TOCSY and 2D tr-NOESY experiments. N6NH-CH, G9NH-CH, G15NH-CH, and 













solvent peaks (Appendix 47). The loss of the G15 and H16 peaks in the Fbg Bβ -thrombin 
sample is consistent with thrombin cleaving Fbg Bβ (5-16) at the R14-G15 peptide bond 
even at the lower NMR pH of 5.6 (Appendix 47 and 50). 1D 1H line broadening 
experiments for free Fbg Bβ (5-16) (Figure 54A, and 54B) and Fbg Bβ (5-16) in the 
presence of bovine thrombin were acquired. Curiously, the R14-NH peak undergoes an 
upfield chemical shift after IIa cleavage suggesting that the R14-NH in the product peptide 
(5-14) encounters more shielded environment. By contrast, the proton attached to side 











Extensive line broadening was seen for residues A13-NH and F10-NH. NOEs are 
numbered from 1 to 30 in the fingerprint, aliphatic and amide regions (Figures 55, 56, and 
57). These include several intra and inter NOEs: 1 (E8H-G9NH), 2 (E8αH-G9NH), 3 
(D5NH-E8H), 4 (A13H-R14NH), 5 (F11H-S12H), 6 (F11αH-S12NH), 7 (A13αH-
R14NH), 8 (G9αH –F10H), 9 (S12αH-A13NH), 10 (S12H-A13NH), 11 (N6H- 
Figure 54: A) 1D Amide proton region of free Fbg Bβ (5-16). B) 1D amide proton region for FpB 






E7NH), 12 (F11H-S12H), 13 (F10αH- F11NH), 14 (D5αH-N6NH), 15 (F11(2,6H)-
F11αH), 16 (F10(2,6H)-F10αH), 17 (F10(2,6H)-F11αH), 18 (F10αH-F11(2,6H)), 19 
(R14NH-γCH2), 20 (F10(2,6H)-F10βH), 21 (F11(2,6H)-F11βH), 22 (F10(3,5H)-F11βH), 23 
(F10(3,5H)-F10βH), 24 (F11(3,5H)-F11βH), 25 (F10βH- F11βH), 26 (G9NH-F10NH), 27 




















Figure 55: 2D NOESY Fingerprint region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. 




























Figure 56: 2D NOESY Aliphatic region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. Sample 
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6) 
 
Figure 57: 2D NOESY Amide region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. Sample 















































































































Much data is available on the binding of Fbg Aα (7-20) to the thrombin active aite 
from previous kinetic, NMR and X-ray crystal studies. Less is known about the binding of 
Fbg Bβ to thrombin. The focus of the current study was Fbg Bβ (D5-H16), a sequence that 
interacts with the active site region of thrombin and can be cleaved at the R14-G15 peptide 
bond. Kinetic parameters for thrombin-catalyzed release of FpB (5-14) were determined. 
In addition, 1D and 2D NMR methods were used to structurally characterize the binding 
of individual FpB residues to the thrombin active site region. 
 HPLC kinetic assay results suggest that thrombin- catalyzed hydrolysis of Fbg Bβ 
(5-16) exhibited a Km value of 1271± 154 µM, a kcat value of 1.0±0.075 s
-1, and a kcat/ Km 
value of 8.2x10-4 ±1.2x10-4 s-1 µM-1. When compared to the kinetic parameters of Fbg Aα 
(7-20),62 Fbg Bβ (5-16) is 2-fold higher in Km and 30-fold lower in kcat value (Table 7 and 
8). Such results reveal that binding interactions for Fbg Bβ (5-16) at the active site are 
weaker and turnover into product is greatly hindered. Fbg Bβ (5-16) is definitely not as 
well optimized to interact with thrombin as Fbg Aα (7-20). Moreover, Fbg Bβ (5-16) 
exhibits the lowest kcat value of the peptide substrates shown in Table 8. With its high Km 
and low kcat, Fbg Bβ (5-16) becomes the weakest peptide substrate in terms of substrate 
specificity (kcat/Km). A careful review of thrombin substrate sequences indicates that 
although the Ala 13 at the P2 position in FpB (5-14) exhibited line broadening in the 
presence of thrombin, it might not be large enough to effectively promote optimal contacts 
with thrombin Y60a and W60d of the thrombin β-insertion loop. In addition, solution NMR 




of a common Proline at the P2 position by making a through space interaction with its 
13GGV15 (P4-P2) region (Table 7 and 8).  
Comparing the kinetics parameters for thrombin catalyzed hydrolysis of Fbg Bβ (5-
16) with those of FXIII AP (28-41) V34F and V34W is also valuable, as both FXIII variants 
contain an aromatic residue at the P4 position.180,181  The presence of such an aromatic 
residue helped both FXIII AP (28-41) V34F and V34W to improve their kcat 3-fold relative 
to FXIII AP (28-41) V34 and 6-fold relative to Fbg Bβ (5-16) (Table 7 and 8). The 
presence of two Phe residues at the P5 and P4 positions of Fbg Bβ (5-16) clearly did not 
improve kcat. 
Another interesting substrate to compare is the PAR series. Even though PAR1 (29-
45) has a similar Km value (1271 µM vs 900 µM)64 as Fbg Bβ (5-16), the substrate 
specificity (kcat/Km) of PAR1 is far higher than that of Fbg Bβ  (5-16) (Table 7 and 8). The 
PAR1 L35 and P37 at the P4 and P2 positions interact optimally below the β insertion loop 
and help orient the PAR1 sequence for effective cleavage by IIa. This benefit is reflected 
in the 35-fold improvement in kcat that occurs with the PAR1 sequence. The PAR4 (38-51) 
sequence has proline at the P4 and P2 positions (
44PVPR47). This arrangement provides 
effective binding contacts with the thrombin active surface leading to a 10-fold 
improvement in Km and kcat relative to Fbg Bβ. Once again, the individual kcat and Km values 
of Fbg Bβ (5-16) reveal that the 10FFSAR14 segment hinders productive binding and 
orientation for IIa cleavage. 
Solution NMR was employed in this project to further explain the weak kinetics of 
Fbg Bβ (5-16). The 1D proton line broadening studies revealed that A13-NH and F10-NH 




G15 and H16 highlighting that thrombin catalyzed cleavage had indeed occurred at the 
R14-G15 peptide bond. (Figure 55,56,57, and 58). Furthermore, a substantial number of 
transferred NOEs were seen for the sequence 8EGFFSAR14. A prevalence of nearest 
neighbor NOEs indicates that there is no evidence of helices adopted by this peptide 
sequence when bound to thrombin. A weak NOE from D5NH-E8CβH suggests the 
possibility of a turn like structure within the N-terminal region of the FpB sequence. 
Previously published molecular modeling studies on Fbg Bβ suggested that F10 at 
the P5 position has hydrophobic interactions with thrombin Y60a and W60d.182  Such 
hydrophobic interactions with the thrombin 60s loop might have led to the extensive line 
broadening of the F10-NH. However, Fbg Bβ F11 at the P4 position did not change peak 
intensity suggesting no interactions with thrombin W215 and E217. Such results agree with 
the in-silico studies, predicting that F11 projects away from thrombin surface.182  Also, no 
NOE cross peaks between F11 (P4) and A13 (P2) were observed, indicating that Fbg Bβ 
(5-16) does not take advantage of a P4 to P2 interaction to stabilize the enzyme-substrate 
complex. By contrast, FXIII AP (28-41) V34L,183 and V34F184 utilized P4 to P2 contacts to 
anchor better on to the IIa surface. A large number of NOEs between FpB F10 and F11 
suggests that their amino acid side chains are interacting with each other through space 
even though both side chains may be oriented in somewhat opposite directions. Unlike 
FpA (7-16),69,183 no NOES were observed between the N- terminal portion of the FpB 
peptide and the P4-P2 region.  
Overall, the HPLC based kinetic assay results that Fbg Bβ (5-16) is a relatively 
poor thrombin substrate because of its high Km and low kcat relative to other common 




take advantage of stabilizing P4 to P2 interactions when bound to thrombin. The presence 
of two Phe residues at the P5 and P4 positions along with a small Ala at the P2 position are 































RESEARCH SUMMARY AND FUTURE DIRECTIONS 
Thrombin with a catalytic triad of His 57, Asp 102, and Ser 195 is highly homologous 
to such serine proteases as trypsin and chymotrypsin.37  Thrombin enzyme specificity is 
controlled through several loops including the 60s loop (or βinsertion loop) and the γ loop 
(or autolysis loop). Another important structural feature is the Na+ ion binding loop which 
contributes to thrombin allostery. The sodium bound form of thrombin is considered to be 
in the “fast” state and thrombin now has procoagulant activity. In contrast, thrombin is 
considered “slow” and leans toward anticoagulant functions in the absence of Na+ ion.45,185 
Secondary anchoring sites rich in positively charged amino acids are called anion binding 
exosite- I and II (ABE I and ABE II) and are present at opposite sides of the active site. 
ABE II interactions with ligands are mainly electrostatic; however, ABE I can have both 
electrostatic and hydrophobic interactions with ligands. Ligands that bind to ABE- I 
include the Protease Activated Receptors PAR1 (49-62),49 PAR3 (44-56),50 and Hirudin 
(54-65).51,161 Ligands binding to ABE-II include glycoprotein GpIbα (269-286),79 
fibrinogen γ´(410-427),53 Haemadin (45-57),54 and heparin.186 
Allosteric communication is possible among the two exosites and between the 
exosites and the active site. Amide hydrogen/deuterium exchange coupled with mass 
spectrometry (HDX-MS) revealed that ligand binding at the exosites exhibited both local 




Effects of Hirudin are only restricted to the ABE I region, whereas PAR3, PAR1, and 
GpIbα showed both local and long-range effects.60 
Thrombin is originally produced as the 72kDa zymogen, Prothrombin (ProT). ProT 
is composed of Fragment-1 (1-155), Fragment-2 (156-271) and a protease domain (272-
579). Fragment-1 contains a Gla domain and disulfide containing Kringle-1. Vitamin K is 
needed for the formation of Gla residues in Fragment -1. Fragment-2 contains Kringle-2, 
the A chain (272-320), and the B chain (321-579). The Thrombin A and B chains together 
constitute the protease domain. ProT is physiologically activated by the Prothrombinase 
complex consisting of a serine proteinase Factor Xa and the cofactor Factor Va, a 
phospholipid membrane, and Ca2+. ProT is anchored to the membrane surface through the 
Gla domain of Fragment 1 (F1).38,187  
In platelets, cleavage of ProT at R271 leads to the formation of the inactive precursor 
Prethrombin-2 (PT2) and Fragment 1.2. Subsequent cleavage at R320 gives rise to the 
active protease α-thrombin (36.7kDa).38,40  α-thrombin can also be autolysed to 
catalytically hindered β and γ- thrombin.39,41  ProT and PT2 have immature anion binding 
exosites called (pro)- ABE-I and II. Upon formation of α-thrombin, these exosites become 
more mature and are called ABE – I and II. These mature exosites help with substrate 
specificity and ligand binding. Unexpectedly, there are certain ligands that can already bind 
to pro-ABE I.125-128  The published literature has provided global KDs for various ligands 
that bind to (pro)-ABE I. Following maturation events at the single amino acid level is 
however missing. Solution NMR studies have revealed that thrombin is highly dynamic 
and there are a few residues in the thrombin ABE I region that cannot be monitored due to 




ability to understand the conformational changes of few regions that occur during thrombin 
activation. To decipher the missing information about maturation events and help to probe 
interactions between various physiological substrates, we divided our research into three 
projects. 
The first project was to probe the maturation events of (pro)- ABE I at the single 
amino acid level by using various solution NMR methods on peptides based on a member 
of the protease activated receptor PAR family. The first peptides studied were derived from 
PAR3. 1D proton line broadening NMR revealed that PAR3 (44-56) and weaker binding 
PAR3G (44-56) could already interact with pro-ABE I on prothrombin. 1H-15N-HSQC 
(Heteronuclear Single Quantum Coherence) NMR titrations were then used to probe 
binding of individual 15N-labeled PAR3G residues (F47, E48, L52, and D54).  PAR3G E48 
and D54 could interact electrostatically with prothrombin and tightened upon thrombin 
maturation.  The higher affinity for PAR3G D54 suggests the region surrounding thrombin 
R77a is better oriented to bind D54 than the interaction between PAR3G E48 and thrombin 
R75. Aromatic PAR3G F47 and aliphatic L52 also both reported on significant changes in 
chemical environment upon conversion of prothrombin to thrombin. The ABE I region 
surrounding the 30s loop was already available than the hydrophobic pocket (F34, L65, 
and I82). These NMR titrations demonstrate that PAR3 residues document structural 
rearrangements occurring during exosite maturation that are missed by reported X-ray 
crystal structures.50,154 
Later, the project was extended to better understand the diversity of PAR ligand   
binding interactions towards zymogen ProT vs mature thrombin. 1D proton line 




already exhibited line broadening with ProT and such broadening increased when bound 
to thrombin. 2D tr-NOESY revealed that PAR1P (49-62) when bound to pro-ABE I 
adopted an extended conformation with the Xaa-Pro bond existing in the trans 
conformation.   
1H-15N HSQC titrations then provided quantitative estimates of binding interactions 
for 15N-labeled PAR peptides interacting with ProT vs thrombin. The F55 of PAR1P 
peptides revealed that the hydrophobic pocket of pro-ABE I (F34, L65, and I82) is 
available for peptide binding, and the affinity increased with mature thrombin. For both 
PAR3154 and PAR1 peptides, a proline to glycine substitution was needed to sufficiently 
weaken the affinity and allow us to characterize the thrombin-peptide interactions. X-
crystal structures reveal almost the same thrombin binding partners for both PAR1 (49-56) 
and PAR3 (44-56). However, the solution NMR methodologies demonstrated that even 
though the PAR residues target the same regions of (pro)- ABE I, the binding affinities of 
K51, E53, and E60 residues in PAR1G (49-62) are weaker than PAR3G (44-56). When 
bound to thrombin, the acidic C-terminal tail of PAR1 (49-62) remains unresolved by 
crystallography.49  NMR titrations are making it possible, for the first time, to evaluate the 
binding affinities of D58 of the PAR1 (58DEEKN62) segment to pro-ABE I and ABE I.  
We also found striking evidence that allosteric communication can be possible 
between ABE I and ABE II. When triply phosphorylated GpIbα (269-282) bound at ABE 
II, it affected the binding affinities of ABE I ligands. Previous HDX-MS studies revealed 
that GpIbα (269-282) had a long-range effect on ABE- I segment L65 to M84.60  Our NMR 




towards the center of the sequences in both PAR3 (44-56) and PAR1 (49-62) than towards 
the C-terminal end. 
The final project of the dissertation was to determine kinetic parameters associated 
with thrombin-catalyzed hydrolysis of Fbg Bβ (5-16). HPLC-based kinetic assay results 
suggested that Fbg Bβ (5-16) has Km value of 1271± 154 µM, kcat value of 1.0±0.075 s
-1, 
and kcat/Km value of 8.2x10
-4 ± 1.2x10-4 s-1 µM-1. A comparison of individual kinetic 
parameters indicates that Fbg Aα (7-20),62 is a better substrate for thrombin than Fbg Bβ 
(5-16). Fbg Bβ is hindered by having both high Km and low kcat values. These limitations 
helped explain why FpB is released from fibrinogen later than that of FpA. FXIII AP (28-
41) V34L and V34F are known to take advantage of an aromatic residue at the P4 position 
to improve optimal contacts with the active site region.183,184  From this project, we 
identified that Fbg Bβ (5-16) was not able to utilize its two aromatic Phe residues at the P4 
and P5 positions to help generate good kinetic parameters when compared to FXIII AP (28-
41) V34F and V34L. Even though the Km values for PAR1 (29-45)64 and Fbg Bβ (5-16) are 
comparable, substrate specificity for PAR1 is 35-fold higher than Fbg Bβ (5-16). PAR1 
(29-45) took advantage of Proline at the P2 position to improve substrate orientation for 
thrombin- catalyzed hydrolysis at the thrombin active site surface. Our solution NMR 
studies then helped to further understand the weak kinetics observed for the hydrolysis of 
Fbg Bβ (5-16). Unlike PAR1, the Phe residues at P4 and at P5 did not show any stabilizing 
through space NOEs with the small Alanine residue at the P2 position. The 
10FFSAR14 
sequence in Fbg Bβ (5-16) plays a key role in forming a stable thrombin- FpB substrate 
complex, however the interactions are not as effective as those found with the other 




Preliminary results and future directions 
Chapter 3 and 4 were mainly focused on calculating individual KD values for amino 
acids that were hypothesized to contact critical residues of thrombin ABE I. It would also 
be valuable to know the global KDs for PAR3P/G (44-56) and PAR1P/G (49-62) in the 
solution NMR buffer conditions of 150 mM NaCl and at pH 6.5. Literature provides global 
KDs for PAR3 (2 µM) and PAR1 (0.5 µM) towards thrombin using a fluorescence based 
approach at very high concentration of NaCl (800 mM) and at pH 8.0.148 We wanted to 
measure the global binding affinities of PAR3P/G (44-56) and PAR1P/G (49-62) using a 
label free technique in solution. For that, a Nano Isothermal Titration Calorimeter (ITC) 
from TA instruments was employed. ITC is a label -free biophysical technique which not 
only gives the binding affinities between a ligand and protein but also reveals the 
thermodynamic parameters of the complex formation. ITC works best if the binding 
affinities fall between the nM to low µM range. Hence, we initiated our ITC project with a 
positive control DNA aptamer whose KD was already published in the literature (64 nM).188 
The 15 base DNA aptamer (HD 1), GGTTGGTGTGGTTGG is documented to bind at 
ABE I of thrombin. Figure 59 represents our ITC binding curve between the DNA aptamer 




















With the success of ITC with the DNA aptamer and bovine thrombin, we proceeded 
to employ ITC for the PAR3- thrombin complex. As all our NMR titrations were performed 
using PPACK-thrombin, the solution conditions were matched in the ITC experiments and 
the PAR3 ligand was titrated into PPACK-IIa. As shown in Figure 60, the curve shape and 
fitting were not as good as seen with the DNA aptamer (Appendix 11). Unlike the ITC 
binding curve between TM and thrombin,188 we found that binding of PAR3 (44-56) to 
thrombin generated low heats. Weak binding and lower ΔH values likely contributed to 
this problem. The enzyme- ligand titration system needs to be better optimized before 
moving on to PAR3G (44-56) or PAR1P/G (49-62) and the ternary complex consisting of 
GpIbα +  thrombin + ABE I ligand. So far, the HSQC NMR titration was a more successful 
strategy for probing the affinities of PAR3 and PAR1 peptides bound to (pro)thrombin. 
Figure 59: ITC binding curve of 2 µL injections of a 50 μM aptamer solution binding to a 












The NMR titration studies from Chapter 3 and 4 revealed the roles of several 
individual 15N- labeled amino acids from PAR3 (44-56) and PAR1 (49-62) that are 
involved in binding to (pro)-ABE I. There are additional residues within the sequences of 
PAR3 and PAR1 that are needed to be explored. A few of them would however be highly 
costly for custom peptide synthesis. An alternative strategy would be to express the 
peptides in E. coli. With this strategy, estimates of the binding affinities for all the 
individual PAR ligand amino acids could be assessed. However to study the direct 
thrombin-ligand contact sites and to observe long-range effects of the ligands on the 
thrombin, the enzyme-ligand NMR titrations should need to be switched to the protein 
perspective. A protocol for expressing 15N-labeled thrombin has already been published189 
and should yield a decent amount of enzyme to carry out NMR studies. The significance 
of having uniformly 15N labeled thrombin expression is the ability to map more thrombin-
peptide contact sites and to understand the consequences of ligand-induced allostery of 
thrombin.  
Figure 60: ITC binding curve of 2 µL injections of a 75 μM aptamer solution binding to a 50 μM 





HPLC- based kinetics and solution structural information for Fbg Bβ (5-16) bound 
to thrombin in Chapter 5 indicated that Fbg Bβ (5-16) has weak kinetic parameters when 
compared to common physiological substrates like Fbg Aα (7-20),62 FXIII (28-41) 
V34X,180,181 PAR1,64 and PAR4.65  An excellent strategy to compare Fbg Bβ binding 
interactions with thrombin would to replace the Ala residue at the P2 position of Fbg Bβ 
(5-16) with a large valine or proline. Also, the P5 position occupied by the bulkier 
phenylalanine could be replaced by a slightly smaller amino acid. These substitutions may 
help in assessing whether there can be any improvements in the kinetic parameters and 
secondary structure when bound to thrombin. This information may help in assessing 
whether it is the thrombin specificity or the availability of Fbg Bβ that plays an important 
role in permitting Fbg Aα (7-20) to be cleaved by thrombin prior to Fbg Bβ (5-16).  
Overall, results from this dissertation project support the conclusion that thrombin 
is a highly dynamic enzyme that is allosterically controlled. Key regions that are affected 
include areas surrounding the active site, the insertion loops, and the two exosites ABE I 
and ABE II.133-135,190  Our studies have demonstrated that physiological peptide ligands 
based on PARs can already bind to the immature pro- ABE I of zymogen ProT. Critical 
maturation events not visible by X-ray crystallography have now been successfully probed 
through solution based NMR methodologies. For the first time, KD values for individual 
15N-labeled amino acids of PAR3154 and PAR1 were estimated. As part of these studies, 
the changes in conformational environments that occur during the maturation events were 
clearly documented. Finally, long-range communication between ABE II and ABE I was 
proven and characterized at the single amino acid level. It would be interesting to know 




ligand perspective. A long-range goal of this research would be to develop new drugs that 
target unique sites within the active site region or the (pro)exosites and thereby modulate 
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An overlay of the 2D 13C-1H natural abundance HSQC NMR spectra of 1 mM PAR3 








All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O 
(pH 6.5). The PAR3 residues are in red whereas the PAR3G are in black.   The expected 






 1D 15N-HSQC NMR titrations of PAR3FD (44-56) in the presence of ProT and 
PPACK- IIa:  
 
  
All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % 
D2O (pH 6.5). A) For the PAR3FD binding studies with ProT, starting complexes 
included 50 M PAR3FD (44-56, 15N-F47, 15N-D54) in 137 M ProT. The serial 
dilutions resulted in ProT to PAR3 ratios that spanned from 3:1 to 0.1:1. B) For 
PPACK- IIa, starting complexes included 50 M PAR3FD (44-56, 15N-F47, 15N-D54) 
in 210 M PPACK- IIa. The serial dilutions resulted in PPACK- IIa to PAR3FD ratios 

















































All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 
6.5). A) For the PAR3FD binding studies with ProT, starting complexes included 50 M 
PAR3FD (44-56, 15N-F47, 15N-D54) in 130 M ProT. The serial dilutions resulted in ProT to 
PAR3FD ratios that spanned from 3:1 to 0.1:1. B) For PPACK -IIa, starting complexes 
included 50 M PAR3FD (44-56, 15N-F47, 15N-D54) in 210 M PPACK-IIa. The serial 
dilutions resulted in PPACK-IIa to PAR3FD ratios that spanned from 4:1 to 0.1:1. 
Representative data sets are shown.  Colors for the HSQC crosspeaks span from blue (highest 













All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % 
D2O (pH 6.5). A) For the PAR3GFD binding studies with ProT, starting complexes 
included 37.5 M PAR3GFD (44-56, 15N-F47, 15N-D54) in 70 M ProT. The serial 
dilutions resulted in ProT to PAR3G ratios that spanned from 2:1 to 0.3:1. B) For 
PPACK- IIa, starting complexes included 37.5 M PAR3GFD (44-56, 15N-F47, 15N-
D54) in 70 M PPACK- IIa. The serial dilutions resulted in PPACK- IIa to PAR3GFD  






15N HSQC NMR titrations of PAR3GEL (44-56) in the presence of ProT and 











All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 
6.5). A) For the PAR3GEL binding studies with ProT, starting complexes included 50 M 
PAR3GEL (44-56, 15N-E48, 15N-L52) in 180 M ProT. The serial dilutions resulted in ProT to 
PAR3G ratios that spanned from 4:1 to 0.1:1.  B) For PPACK- IIa, starting complexes 
included 50 M PAR3GEL (44-56, 15N-E48, 15N-L52) in 211 M PPACK- IIa. The serial 
dilutions resulted in PPACK- IIa to PAR3GEL ratios that spanned from 4:1 to 0.1:1. 






Determination of Binding Affinity (KD) for 15N-labeled F47 and D54 of PAR3GFD 





























For this NMR titration series, the peptide ligand concentration was kept constant and the ProT 
and PPACK-R77aA IIa concentrations were serially diluted.  As a result, the NMR titrations 
were measuring the binding of protein to a defined peptide concentration.  A) Interactions 
between PPACK-R77aA IIa and PAR3G 15N-D54 led to a KD = 168 ± 88 µM and B) ProT and 
PAR3G 15N-F47 led to a KD = 173 ± 85 µM. NMR titrations were done in duplicate.  The 
reported KD values were determined using in-house scripts written using Python. The term 
|Δδobs| 15Nppm = δ15NBound – δ15N Free reflects the absolute difference in chemical shift between 
the bound and free states of the particular 15N-amide.  Error analysis was carried out using a 
Monte-Carlo approach assuming a 10% error in the serially diluted protein samples.   See 






Determination of Binding Affinity (KD) for 15N-labeled L52 and E48 of PAR3GFD 















































For this NMR titration series, the peptide ligand concentration was kept constant and the 
ProT and PPACK-IIa concentrations were serially diluted.  As a result, the NMR titrations 
were measuring the binding of protein to a defined peptide concentration.  A) Interactions 
between ProT and PAR3G 15N-L52 led to a KD = 124 ± 27 µM,  B) ProT and PAR3G 15N-
E48 led to a KD = > 200 µM, and C) PPACK-IIa and PAR3G 15N-L52 led to a KD = 47 ± 
6 µM.  NMR titrations were done in triplicate.  The reported KD values were determined 
using in-house scripts written using Python.  The term |Δδobs| 15Nppm = δ15NBound – δ15N 
Free reflects the absolute difference in chemical shift between the bound and free states of 
the particular 15N-amide. Error analysis was carried out using a Monte-Carlo approach 
assuming a 10% error in the serially diluted protein samples. See Materials and Methods 






























D54, already broadened at 0.3:1 
F47 
4:1 to  0.14:1 
1H-15N 2D HSQC titration of PAR3GFD (44-56) when bound to thrombin.  
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 





1H-13C HSQC spectra of PAR1 (49-62) [A] used for assigning aromatics in 1H-1H 




























A) 1H-13C HSQC spectra of 1 mM PAR1 (49-62). B) 1H-1H 2DNOESY of 780 µM PAR1 





Procedure for ITC experiment between DNA aptamer and thrombin: 
558 nmole of aptamer (HD 1, GGTTGGTGTGGTTGG) was solubilized in 500 µL 
dI water. 1.12 mM aptamer was then aliquoted in 20 tubes, lyophilized, and later stored at 
-80ºC until needed. One the day of experiment, bovine thrombin was buffer exchanged into 
50 mM Bis-tris propane (pH 7.4), 150 mM NaCl through dialysis. 75 µL of aptamer 
samples were reconstituted using the same buffer. 500 µL of 7 µM bovine thrombin was 
placed in the calorimetric cell of the Nano ITC (New Castle, DE). 2 µL of DNA aptamer 
was added 25 times into the cell followed by an initial delay of 250 s. The final 
concentration of DNA aptamer in the calorimetric cell was 50 µM. During data processing 
using the Nano Analyze, initial heat was masked as it resulted from the heats of dilution. 
The individual heats were then plotted as a function of the molar ratio, and nonlinear 
regression of the data was performed using Nano Analyze software supplied with the 














Procedure for ITC experiment between PAR3 (44-56) and thrombin: 
Prior to the titration bovine thrombin was incubated with a 4-fold excess of PPACK 
at 37ºC for 30 mins.  Later, PPACK-thrombin was buffer exchanged into 25 mM H3PO4, 
150 mM NaCl, 0.2 mM EDTA, (pH 6.5). Lyophilized PAR3 (44-56) was solubilized into 
the same buffer. Since the affinity of PAR3 (44-56) for thrombin is not as strong as the 
DNA aptamer, quite an excess of thrombin concentration was tested. 500 µL of 50 µM 
bovine thrombin was placed into the calorimetric cell of the Nano ITC (New Castle, DE). 
2 µL of PAR3 (44-56) was added 25 times into the cell followed by the initial delay of 250 
s. The final concentration of PAR3 (44-56) was 75 µM. Same software and processing 















2D TOCSY Fingerprint region of 1 mM PAR3 (44-56). Sample was 





















2D TOCSY Aliphatic region of 1 mM PAR3 (44-56). Sample was prepared 





















2D TOCSY Aliphatic region of 1 mM PAR3 (44-56). Sample was prepared 







2D TOCSY Fingerprint region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was 







  2D TOCSY Aliphatic region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was 






APPENDIX 16  
  
2D TOCSY Amide region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was 







2D tr-NOESY Fingerprint region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample 







2D tr-NOESY Aliphatic region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was 







2D tr-NOESY Amide region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was 







2D TOCSY Fingerprint region of 1 mM PAR3G (44-56). Sample was prepared in 







2D TOCSY Aliphatic region of 1 mM PAR3G (44-56). Sample was prepared in 







2D TOCSY Amide region of 1 mM PAR3G (44-56). Sample was prepared in 25mM 







2D TOCSY Fingerprint region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample 







2D TOCSY Aliphatic region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was 








2D TOCSY Amide region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was 








2D NOESY Fingerprintregion of 1 mM PAR3G (44-56) + 76 μM ProT. Sample 







2D NOESY Aliphatic region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was 







2D NOESY Amide region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was 







2D TOCSY Fingerprint region of 1 mM PAR1P (49-62). Sample was prepared in 







2D TOCSY Aliphatic region of 1 mM PAR1P (49-62). Sample was prepared in 







2D TOCSY Amide region of 1 mM PAR1P (49-62). Sample was prepared in 25mM 







2D TOCSY Fingerprint region of 1 mM PAR1P (49-62) + 59 μM ProT Sample was 







2D TOCSY Aliphatic region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was 







2D TOCSY Amide region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was 







2D NOESY Fingerprint region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample 







2D NOESY Aliphatic region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was 







2D NOESY Amide region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was 







2D TOCSY Fingerprint region of 1 mM PAR1G (49-62). Sample was prepared in 







2D TOCSYAliphatic region of 1 mM PAR1G (49-62). Sample was prepared in 







2D TOCSYAmide region of 1 mM PAR1G (49-62). Sample was prepared in 25mM 







2D TOCSY Fingerprint region of 830 μM  PAR1G (49-62) + 83 μM ProT. Sample 







2D TOCSY Aliphatic region of 830 μM  PAR1G (49-62) + 83 μM ProT. Sample 







2D TOCSY Amide region of 830 μM  PAR1G (49-62) + 83 μM ProT. Sample was 







2D NOESY Fingerprint region of 830 μM  PAR1G (49-62) + 83 μM ProT. Sample 







2D NOESY Aliphatic region of 830 μM  PAR1G (49-62) + 83 μM ProT. Sample 







2D NOESY Amide region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample was 









2D TOCSY Fingerprint region of 1.5 mM FpB (5-16). Sample was prepared 
in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6): 
  region of 1.5 mM Fbg Bβ (5-16). Sample was prepared in 25mM 






2D TOCSY Aliphatic region of 1.5 mM Fbg Bβ (5-16). Sample was prepared in 






2D TOCSY Amide region of 1.5 mM Fbg Bβ (5-16). Sample was prepared in 







 2D TOCSY Fingerprint region of 1.5 mM Fbg Bβ (5-16) and 160 µM 
thrombin. Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM 





2D TOCSY Aliphatic region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. 
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 





APPENDIX 52  
2D TOCSY Amide region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. 
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 









ABE-I     Anion binding exosite – I  
ABE-II     Anion binding exosite – II  
AP      Activation peptide 
AT     Antithrombin 
AUC      Analytical Ultra Centrifugation 
EDTA     Ethylenediaminetetraacetate 
Fbg Aα     Fibrinogen Aα chain 
Fbg Bβ     Fibrinogen Bβ chain 
FpA      Fibrinopeptide A 
FpB      Fibrinopeptide B 
FXIII      Transglutaminase FXIII 
FXIII AP                                            Transglutaminase FXIII Activation Peptide 
Gla     γ-carboxyglutamic acid 
GpIbα     Glycoprotein Ibα found on the receptor 
HDX-MS              Hydrogen Deuterium Exchange -Mass  
Spectrometry 
HK/HMWK     High Molecular Weight Kininogen 
His 57     Histidine at 57th position of the thrombin sequence 
HSQC     Heteronuclear Single Quantum Coherence 
ITC     Isothermal Titration Calorimetry 
kcat      Product turnover/ Catalytic Constant 
KD     Binding affinity 
Km      Michaelis Constant 
kcat/Km     Specificity Constant 
koff     Dissociation Rate Constant 
kon     Association Rate Constant 
MALDI-TOF MS    Matrix Assisted Laser Desorption Ionization  
Time of Flight Mass Spectrometry 
NMR      Nuclear Magnetic Resonance 
PAI1     Plasminogen Activator Inhibitor 1 
PAR      Protease Activated Receptor 
PAR1P     Protease Activated Receptor-1 with Proline at 54th  
position 
PAR1G    Protease Activated Receptor-1 with Glycine at 54th  
position 
PAR3      Protease Activated Receptor-3 
PAR3G    Protease Activated Receptor-3 with Glycine at 51st  
position 
PPACK                                              D-Phe-Pro-Arg chloromethyl ketone 
ProT      Prothrombin 




PT2      Prethrombin 2 
R     Gas constant 
RP-HPLC   Reversed Phase High Performance Liquid 
Chromatography 
R77a Arginine at 77th position of the thrombin sequence, 
“a” indicates first residue in 70 loop 
R77aA Arginine at 77th position of the thrombin is replaced 
by alanine 
SLEX      Systematic Evolution of Ligands by Exponential  
Enrichment 
T     Absolute temperature 
T1     Spin-lattice Relaxation with time constant T1 
T2      Transverse Relaxation with time constant T2 
TF     Tissue factor 
TFPI     Tissue Factor Pathway Inhibitor 
TM      Thrombomodulin 
vWF     von Willebrand Factor 
W60d  Trptophan at 60th position of the thrombin 
sequence, “d” indicates fourth residue in 60s loop 
Y60a      Tyrosine at 60th position of the sequence, “a”  
indicates first residue in 60s loop 
YP     Phosphotyrosine 
1D      One Dimensional 
2D      Two Dimensional  
2D TOCSY     Two-Dimensional Total Correlational  
Spectroscopy 
2D tr-NOESY                                    Two- Dimensional Transferred Nuclear  
Overhauser Spectroscopy 
IIa      Thrombin 
ω     Resonance Frequency  
τc     Rotational Correlation Time 
H                Change in enthalpy  
ΔG                Change in Gibbs Free energy  
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